WO2012018115A9 - 線維化組織から正常組織を再生するための組成物 - Google Patents
線維化組織から正常組織を再生するための組成物 Download PDFInfo
- Publication number
- WO2012018115A9 WO2012018115A9 PCT/JP2011/067953 JP2011067953W WO2012018115A9 WO 2012018115 A9 WO2012018115 A9 WO 2012018115A9 JP 2011067953 W JP2011067953 W JP 2011067953W WO 2012018115 A9 WO2012018115 A9 WO 2012018115A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- tissue
- cells
- substance
- fibrosis
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Definitions
- the present invention relates to a composition and method for regenerating normal tissue from fibrotic tissue.
- Tissue fibrosis is caused by excessive production and accumulation of extracellular matrix, mainly collagen, in the tissue.
- extracellular matrix mainly collagen
- the damaged tissues are replaced with extracellular matrix for repair, but if the damage is severe or such stimuli become chronic In such cases, the extracellular matrix accumulates excessively and the tissue cannot perform its function sufficiently.
- Fibrosis is observed in various organs such as liver, pancreas, lung, kidney, bone marrow, and heart, and collagen-producing cells such as myofibroblasts are considered to be involved in the pathological condition.
- fibrosis is an irreversible phenomenon, and it has been thought that once fibrotic tissue does not return to its original state, but recently, fibrosis is reversible, and the fibrosis stimulation as described above Several reports have been made to suggest that the loss of the extracellular matrix accumulated in tissues decreases (see Non-Patent Documents 1 to 3).
- the fibrosis of tissue includes fibrosis derived from viral infections, alcohol consumption, drugs, etc., not only those whose etiology is clear and can be removed, but also fibrosis whose direct etiology is unknown, for example, , Idiopathic cirrhosis, idiopathic pulmonary fibrosis, idiopathic myelofibrosis, etc., or those with a direct etiology that is unknown but difficult to remove, such as primary bile Also included are liver cirrhosis, non-alcoholic steatohepatitis (NASH) -derived liver fibrosis, primary sclerosing cholangitis and the like. Tissues with fibrosis that are difficult to remove such pathogenesis are constantly exposed to fibrotic
- An object of the present invention is to provide a composition and method for therapeutically regenerating normal tissue in a tissue in which fibrosis is present.
- the inventors of the present invention have been able to reduce collagen accumulated in a fibrotic tissue that is continuously receiving fibrosis stimulation while continuing intensive research to solve the above problems.
- the inventors have found that normal tissue can be regenerated from fibrotic tissue by removing accumulated collagen and securing a space in which stem cells can proliferate and differentiate, thereby completing the present invention.
- a pharmaceutical composition for regenerating normal tissue from fibrotic tissue comprising a collagen-reducing substance.
- the collagen-reducing substance is selected from the group consisting of a substance that suppresses collagen production by collagen-producing cells, a substance that promotes collagen degradation, and a substance that inhibits a collagen degradation inhibitor, Pharmaceutical composition.
- the pharmaceutical composition according to (1) or (2) further including a targeting agent for collagen-producing cells in fibrotic tissue.
- the targeting agent is a retinoid.
- the above (1) to (5) for regenerating normal tissue from fibrotic tissue in a space for proliferation / differentiation of stem cells generated by reducing collagen accumulated in fibrotic tissue A pharmaceutical composition according to any one of the above.
- Substances that suppress collagen production by collagen-producing cells are TGF ⁇ inhibitory substance, HGF or its production promoting substance, PPAR ⁇ ligand, angiotensin inhibitory substance, PDGF inhibitory substance, relaxin or its production promoting substance, production of extracellular matrix components
- the pharmaceutical composition according to any one of the above (2) to (6) which is selected from the group consisting of a substance that inhibits secretion, a cell activity inhibitor, a cell growth inhibitor, and an apoptosis inducer.
- the pharmaceutical composition according to any one of (2) to (6) above, wherein the substance that promotes collagen degradation is collagenase or a substance that promotes production thereof.
- the pharmaceutical composition according to any one of (2) to (6) above, wherein the substance that suppresses a collagen degradation inhibitor is a TIMP inhibitor.
- normal tissue can be regenerated from fibrotic tissue that has been thought to not regenerate normal tissue.
- normal tissue can be therapeutically regenerated from the fibrotic tissue, and a new regenerative treatment of the fibrotic disease becomes possible.
- the present invention enables treatment of fibrotic tissues that are continuously exposed to fibrotic stimulation, and fibrotic diseases for which there has been no effective therapeutic method or fibers for which only an organ transplantation has been used. Since medical treatment of all fibrotic diseases including fibrosis is realized, a great contribution can be expected to medical treatment and veterinary medicine.
- FIG. 1 is a photograph showing the overall appearance of a liver collected from a test rat and an Azan-stained image of a representative section thereof.
- FIG. 2 is a photograph showing the localization of ⁇ -SMA in a representative section of the liver collected from the test rat.
- FIG. 3 is a fluorescence image showing the localization of DAPI and GFP at the site of liver stem cell transplantation.
- FIG. 4 shows a bright field image and a GFP fluorescence image of the liver stem cell transplantation site.
- FIG. 5A is a photographic view comparing DAPI and GFP fluorescence images with a GFAP antibody-stained fluorescence image in a VA-lip siRNAgp46 administration group (magnification 200 times).
- FIG. 5B is a photographic view comparing DAPI and GFP fluorescence images with a GFAP antibody-stained fluorescence image in a VA-lip siRNAgp46-administered group (magnification 400 times).
- FIG. 6 is a photographic view comparing DAPI and GFP fluorescence images with an ⁇ -SMA antibody fluorescence image at a magnification of 200 times in the VA-lip siRNAgp46 administration group.
- FIG. 7 is a photographic view comparing DAPI and GFP fluorescence images with an albumin antibody fluorescence image at a magnification of 200 times in the VA-lip siRNAgp46 administration group.
- FIG. 8 is a photographic view comparing DAPI and GFP fluorescence images with a CK19 antibody fluorescence image at a magnification of 200 times in the VA-lip siRNAgp46 administration group.
- FIG. 6 is a photographic view comparing DAPI and GFP fluorescence images with an ⁇ -SMA antibody fluorescence image at a magnification of 200 times in the VA-lip siRNAgp46 administration group.
- FIG. 7 is a photographic view comparing DAPI and GFP fluorescence images with an albumin antibody fluorescence image at a magn
- FIG. 9A is a photographic diagram comparing DAPI and GFP fluorescence images with a ve-CAD antibody fluorescence staining image in the VA-lip siRNAgp46 administration group (magnification 200 times).
- FIG. 9B is a photographic diagram comparing DAPI and GFP fluorescence images with a ve-CAD antibody fluorescence staining image in the VA-lip siRNAgp46 administration group (400 ⁇ magnification).
- FIG. 10 is a photographic view comparing the DAPI and GFP fluorescence images and the fluorescence stained images with albumin antibody at a magnification of 200 times in the VA-lip siRNAgp46 administration group where hepatic stem cells were not transplanted.
- FIG. 11 is a fluorescence image showing the intracellular distribution of FAM-labeled siRNA in rat pancreatic stellate cells.
- FIG. 12 is a graph showing the results of FACS analysis for siRNA incorporated into rat pancreatic stellate cells.
- FIG. 13 is a western blot image showing suppression of gp46 expression in rat pancreatic stellate cells by siRNAgp46.
- A shows the difference in inhibitory effect depending on the concentration of VA-lip siRNAgp46, and B shows the duration of the inhibitory effect.
- FIG. 14 is a graph quantifying the amount of collagen produced after 72 hours in untreated cells and cells treated with VA-lip siRNAgp46 and VA-lip siRNArandom, respectively.
- FIG. 15 is a photograph showing the specific delivery of VA-lip siRNAgp46 to pancreatic stellate cells in DBTC-treated rats.
- a and B are immunostained images of anti- ⁇ -SMA antibody and anti-FITC antibody, respectively, of a pancreas section of a rat treated with VA-lip siRNAgp46-FITC and Lip siRNAgp46-FITC three times every other day.
- the stained images a to d on the right side are enlarged images of regions represented by the corresponding symbols in the left stained image.
- C is a stained image of a liver section of a rat treated with VA-lip siRNAgp46-FITC three times every other day by means of Azan-Mallory staining, anti- ⁇ -SMA antibody staining or anti-FITC antibody staining.
- D to F are stained images of the rat lung, spleen and retina 24 hours after intravenous administration of VA-lip siRNAgp46-FITC, stained with anti-CD68 antibody or anti-FITC antibody.
- FIG. 16 shows the results of the administration of VA-lip siRNAgp46 (siRNA 0.75 mg / kg) on the 14th day after DBTC treatment in the pancreas on days 0, 1, 2, 3 and 4 after administration of VA-lip siRNAgp46. It is the figure which showed the expression of gp46 protein.
- A represents the results of Western blotting of the pancreatic cell debris, and B represents the results of quantitative concentration analysis standardized with ⁇ -actin.
- FIG. 17 shows the effect of VA-lip siRNAgp46 on DBTC-induced pancreatic fibrosis.
- A represents an Azan-Mallory-stained image of a pancreatic section of a DBTC-treated rat to which VA-lip siRNAgp46, Lip siRNAgp46 or PBS was administered 10 times.
- B is a graph quantified by computer image analysis of a positive region in A's Azan-Mallory stained image. Data are calculated from 6 fields randomly extracted from 6 rats in each group, and are expressed as mean ⁇ standard deviation.
- C is a graph showing the content of hydroxyproline in the pancreas. Data are expressed as mean ⁇ standard deviation.
- FIG. 18 shows the effect of VA-lip siRNAgp46 on DBTC-induced pancreatic fibrosis.
- A represents an ⁇ -SMA stained image in the pancreas of a DBTC-treated rat after VA-lip siRNAgp46 treatment.
- B is a graph in which the ⁇ -SMA positive region in A is quantified by computer image analysis. Data are calculated from 6 fields randomly extracted from 6 rats in each group, and are expressed as mean ⁇ standard deviation.
- FIG. 19 shows the regeneration of normal tissue from fibrotic pancreatic tissue by VA-lip siRNAgp46.
- A shows a hematoxylin-eosin-stained image of the pancreas after VA-lip siRNAgp46 (right) and Lip siRNAgp46 (left) were administered 10 times to DBTC-treated rats.
- the lower figure is an enlarged view of regions a and b in the upper figure, respectively.
- B is a graph showing the pancreas weight of DBTC-treated rats.
- FIG. 20 is a graph showing the effect of the presence or absence of space around stem cells on the differentiation of stem cells.
- shaft shows the area of an albumin positive colony.
- FIG. 21 is a graph showing the effect of the presence or absence of space around stem cells on the proliferation of stem cells. The vertical axis represents an index of the proliferation rate of stem cells.
- the present invention relates to a composition for regenerating normal tissue from fibrotic tissue, which contains a collagen-reducing substance.
- the “collagen-reducing substance” means any substance that can reduce the amount of collagen accumulated in a tissue.
- collagen accumulation in fibrotic tissues is thought to be due to the balance between collagen production and degradation being biased toward the production side.
- substances that suppress collagen production substances that promote the degradation of collagen and substances that suppress substances that inhibit the substances may be included.
- examples of the collagen-reducing substance include, but are not limited to, substances that suppress collagen production by collagen-producing cells, substances that promote collagen degradation, and substances that inhibit collagen degradation-inhibiting substances.
- Collagens in the present invention are not particularly limited, but collagens involved in fibrosis, such as type I, III, and V collagen, are preferable, and type I collagen present in the largest amount in fibrotic tissue is particularly preferable.
- a collagen-producing cell means any cell that produces collagen in a fibrotic tissue, and includes, for example, activated stellate cells, myofibroblasts, and the like.
- Activated stellate cells and myofibroblasts are considered to be the primary collagen production sources in fibrotic tissue and are characterized by the expression of ⁇ -SMA ( ⁇ smooth muscle actin). Therefore, activated stellate cells and myofibroblasts in the present invention are identified by immunostaining using a detectably labeled anti- ⁇ -SMA antibody.
- Substances that suppress collagen production by collagen-producing cells include any drug that directly or indirectly suppresses physical, chemical and / or physiological effects of the cells related to collagen accumulation in fibrotic tissues, without being limited thereto, for example, TGF ⁇ (Transforming growth factor-beta) inhibitor, HGF (Hepatocyte growth factor) or its production promoting substance, PPAR ⁇ (Peroxisome proliferator-activated receptor gamma) ligand, angiotensin inhibitor, PDGF (Platelet-derived) growth factor) inhibitors, relaxin or its production promoters, substances that inhibit the production and secretion of extracellular matrix components, cell activity inhibitors, cell growth inhibitors, apoptosis inducers, and the like.
- TGF ⁇ Transforming growth factor-beta
- HGF Hepatocyte growth factor
- PPAR ⁇ Peroxisome proliferator-activated receptor gamma
- angiotensin inhibitor angiotensin inhibitor
- PDGF Platinum-derived growth factor
- TGF ⁇ inhibitors include, but are not limited to, truncated TGF ⁇ type II receptors (Qi et al., Proc Natl Acad Sci U S A. 1999; 96 (5): 2345-9), soluble TGF ⁇ II type receptors (George et al., Proc Natl Acad Sci U S A. 1999; 96 (22): 12719-24), TGF ⁇ activity inhibitors such as anti-TGF ⁇ antibodies, RNAi molecules against TGF ⁇ , TGF ⁇ such as ribozymes and antisense nucleic acids Production inhibiting substances, vectors expressing them, cells transformed with these, and the like can be mentioned.
- the TGF ⁇ inhibitor inhibits the activity and / or production of TGF ⁇ 1.
- Examples of the production promoting substance for HGF or relaxin include, but are not limited to, nucleic acids encoding HGF or relaxin, expression constructs containing the same, expression vectors containing them, and cells transformed with these.
- Examples of the PPAR ⁇ ligand include, but are not limited to, endogenous ligands such as 15-deoxy- ⁇ 12,14-prostaglandin J2, nitrolinoleic acid, oxidized LDL (low density lipoprotein), long chain fatty acids, eicosanoids, troglitazone, Examples include exogenous ligands such as thiazolidinedione drugs such as pioglitazone, rosiglitazone, balaglitazone, and riboglitazone, and non-steroidal anti-inflammatory drugs.
- angiotensin inhibitor examples include, but are not limited to, angiotensin receptor antagonists such as telmisartan, losartan, valsartan, candesartan cilexetil, olmesartan medoxomil, irbesartan, and the like.
- Angiotensin includes angiotensin I, II, III and IV.
- angiotensin receptor examples include, but are not limited to, an angiotensin type 1 receptor (AT1).
- PDGF inhibitors include, but are not limited to, for example, PDGF activity inhibitors such as anti-PDGF antibodies, PDGF production inhibitors such as RNAi molecules against PDGF, ribozymes and antisense nucleic acids, vectors expressing these, and Examples include transformed cells.
- substances that inhibit the production and secretion of extracellular matrix components include, but are not limited to, the suppression of the expression of extracellular matrix components such as collagen, proteoglycan, tenascin, fibronectin, thrombospondin, osteopontin, osteonectin, and elastin.
- substances such as RNAi molecules, ribozymes and antisense nucleic acids, substances having a dominant negative effect such as dominant negative mutants, vectors expressing them, cells transformed with these, and the like.
- HSP Heat (Heat)
- shock protein 47 inhibitors for example, HSP47 expression inhibitory substances such as RNAi molecules against HSP47, ribozymes, antisense nucleic acids, etc., or substances having a dominant negative effect such as dominant negative mutants of HSP47, vectors expressing these, and Examples thereof include cells transformed with these.
- cytostatic substances include, but are not limited to, alkylating agents (eg, ifosfamide, nimustine, cyclophosphamide, dacarbazine, melphalan, ranimustine, etc.), antitumor antibiotics (eg, idarubicin, epirubicin, Daunorubicin, doxorubicin, pirarubicin, bleomycin, pepromycin, mitoxantrone, mitomycin C, etc.), antimetabolite (eg, gemcitabine, enocitabine, cytarabine, tegafur uracil, tegafur gimeracil oteracil potassium combination drug, doxyfluridine, hydroxycarbamide, Fluorouracil, methotrexate, mercaptopurine, etc.), etoposide, irinotecan, vinorelbine, docetaxel, paclitaxel, vincristine,rance
- Examples of the cell activity inhibitor include, but are not limited to, a sodium channel inhibitor.
- Examples of the apoptosis inducer include, but are not limited to, compound 861, gliotoxin, atorvastatin, and the like.
- Examples of the substance that promotes the degradation of collagen include, but are not limited to, various collagenases or substances that promote production thereof.
- Examples of collagenase include, but are not limited to, MMP families such as MMP (Matrix metalloproteinase) 1, 2, 3, 9, 13, 14 and the like.
- Examples of the collagenase production promoting substance include, but are not limited to, a nucleic acid encoding collagenase, an expression construct containing the same, an expression vector containing them, and a cell transformed with these.
- TIMP tissue inhibitor of metalloproteinase
- TIMP1 tissue inhibitor of metalloproteinase
- TIMP2 tissue inhibitor of metalloproteinase
- a TIMP activity inhibiting substance such as an antibody against TIMP, an RNAi molecule against TIMP
- a TIMP production inhibiting substance such as a ribozyme, an antisense nucleic acid, and a vector for expressing them And cells transformed with these.
- the RNAi molecule in the present invention includes siRNA (small interfering RNA), miRNA (micro RNA), shRNA (short hairpin RNA), ddRNA (DNA-directed RNA), piRNA (Piwi-interacting RNA), rasiRNA (repeat associated siRNA). RNA and their variants are also included.
- the nucleic acid in the present invention includes RNA, DNA, PNA, or a complex thereof.
- fibrotic tissue means a tissue in which an extracellular matrix centering on collagen is accumulated more than normal.
- the extracellular matrix include, but are not limited to, collagen, proteoglycan, tenascin, fibronectin, thrombospondin, osteopontin, osteonectin, elastin and the like.
- the amount of collagen accumulated in the tissue can be determined by using, for example, the amount of hydroxyproline in the tissue as an indicator, or collagen staining (for example, Masson / Trichrome staining, Azan staining, Sirius red staining, Elastica / Wangyson staining, etc.) It can be quantified by applying and analyzing images.
- the amount of extracellular matrix in the fibrotic tissue according to the present invention is 5% or more, 10% or more, 25% or more, 50% or more, 100% or more, 200% or more, 300% or more, 400% compared to normal tissue. It may be more than or 500%. Since it is considered that collagen production by activated stellate cells and / or myofibroblasts contributes to tissue fibrosis, the fibrotic tissue in the present invention is typically activated stellate cells and / or Or it contains myofibroblasts.
- the fibrotic tissue may be any tissue in the body as long as it has the above characteristics, and is not limited to, for example, liver, pancreas, lung, kidney, bone marrow, vocal cord, larynx, oral cavity, heart Spleen, mediastinum, retroperitoneum, uterus, skin, mammary gland, intestinal tract, etc.
- the fibrotic tissue may be an affected area of various organ fibrosis.
- organ fibrosis include, but are not limited to, for example, liver fibrosis, cirrhosis, vocal cord scar formation, vocal cord mucosal fibrosis, laryngeal fibrosis, pulmonary fibrosis, pancreatic fibrosis, myelofibrosis, myocardial infarction, Myocardial fibrosis after myocardial infarction, myocardial fibrosis, endocardial myocardial fibrosis, splenic fibrosis, mediastinal fibrosis, submucosal fibrosis, intestinal fibrosis (eg, associated with inflammatory bowel disease) Retroperitoneal fibrosis, uterine fibrosis, scleroderma, breast fibrosis and the like.
- Liver fibrosis and cirrhosis in the present invention are not only caused by viral infections such as hepatitis B virus and hepatitis C virus, alcohol drinking, fatty liver, parasitic infection, inborn errors of metabolism, hepatotoxic substances, etc. Including those not specified.
- cirrhosis in the present invention is not limited, for example, Charcot cirrhosis, Todd cirrhosis, primary biliary cirrhosis, monolobal cirrhosis, secondary biliary cirrhosis, obstructive cirrhosis, biliary cirrhosis, biliary cirrhosis, Atrophic cirrhosis, nutritional cirrhosis, post-necrotic cirrhosis, post-hepatic cirrhosis, nodular cirrhosis, mixed cirrhosis, small nodular cirrhosis, compensatory cirrhosis, nodular cirrhosis, septal cirrhosis, idiopathic cirrhosis, decompensated Liver cirrhosis, periportal cirrhosis, portal cirrhosis, alcoholic cirrhosis and the like.
- pulmonary fibrosis includes not only pulmonary fibrosis in a narrow sense but also pulmonary fibrosis in a broad sense including coexistence with interstitial pneumonia.
- pulmonary fibrosis refers to any interstitial pneumonia such as viral pneumonia, fungal pneumonia, infectious interstitial pneumonia accompanying mycoplasma pneumonia, rheumatoid arthritis, systemic scleroderma, dermatomyositis, multiple Interstitial pneumonia associated with collagen disease such as hereditary myositis, mixed connective tissue disease (MCTD), interstitial pneumonia associated with radiation exposure, anticancer agents such as bleomycin, Chinese medicine such as Shosaikoto, interferon, Drug-induced interstitial pneumonia due to antibiotics, paraquat, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, acute interstitial pneumonia, idiopathic organized pneumonia, respiratory bronchiolitis-related interstitial lung disease It can be attributed to idiopathic interstitial pneumonia
- myelofibrosis includes not only primary myelofibrosis but also secondary myelofibrosis.
- Secondary myelofibrosis is not limited to acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, polycythemia vera, primary thrombocythemia, myelodysplastic syndrome, multiple myeloma, malignant Including diseases such as lymphoma, carcinoma, systemic lupus erythematosus, systemic progressive sclerosis, secondary to radiation.
- Renal fibrosis in the present invention may be any interstitial nephritis such as streptococcal nephritis, staphylococcal nephritis, pneumococcal nephritis, chickenpox, hepatitis B, hepatitis C, viral nephritis associated with HIV, malaria, etc.
- interstitial nephritis such as streptococcal nephritis, staphylococcal nephritis, pneumococcal nephritis, chickenpox, hepatitis B, hepatitis C, viral nephritis associated with HIV, malaria, etc.
- Nephritis associated with vascular immune diseases such as interstitial nephritis, purpura nephritis, polyarteritis, rapidly progressive glomerulonephritis, interstitial nephritis associated with radiation exposure, gold preparation, NSAIDs, penicillamine, bleomycin and other anticancer agents
- the fibrotic tissue is continuously subjected to fibrosis stimulation.
- fibrosis stimulus means any stimulus that induces fibrosis and includes, but is not limited to, for example, oxidative stress, hypoxia, inflammation, apoptosis (Ghiassi-Nejad et al., Expert Rev Gastroenterol Hepatol. 2008; 2 (6): 803-16).
- Such tissues include, for example, fibrotic tissues causing chronic inflammation, tissues that are constantly exposed to cytotoxic substances (for example, liver tissues in which bile stasis occurs due to bile duct diseases, etc.) Can be mentioned.
- Such tissues also have fibrosis of unknown direct etiology, such as idiopathic cirrhosis, idiopathic pulmonary fibrosis, idiopathic myelofibrosis, etc.
- Unclear cause or difficult to remove such as primary biliary cirrhosis, nonalcoholic steatohepatitis (NASH) -derived liver fibrosis, primary sclerosing cholangitis, idiopathic pulmonary fibrosis, idiopathic Pulmonary fibrosis derived from interstitial pneumonia, primary myelofibrosis, renal fibrosis derived from idiopathic interstitial nephritis, inflammatory bowel disease (eg Crohn's disease, ulcerative colitis, etc.), systemic scleroderma, etc. Including affected tissues.
- “regenerating normal tissue from fibrotic tissue” means restoring a tissue that has been altered by fibrosis to a state where fibrosis is milder. In other words, as fibrosis progresses, the tissue is replaced with fibrous tissue centered on the extracellular matrix, but this flow is reversed to replace the increased fibrous tissue with the original normal tissue. It is regeneration of normal tissue from fibrotic tissue in the invention. Therefore, the regeneration of normal tissue from fibrotic tissue in the present invention includes not only restoring the fibrotic tissue completely to the original state but also partially restoring the fibrotic tissue to the original state.
- the degree of normal tissue regeneration may be evaluated based on normalization of tissue structure, reduction of the area occupied by fibrous tissue, expansion of the area occupied by normal tissue, etc. by histological examination such as a biopsy sample. If abnormal biochemical indicators resulting from fibrosis are observed before treatment with the present composition, evaluation may be made by improving the indicators.
- one aspect of the present invention is the above pharmaceutical composition for regenerating normal tissue from fibrotic tissue in a space for stem cell proliferation / differentiation produced by reducing collagen accumulated in fibrotic tissue.
- the stem cells are not limited to, for example, those originally present in fibrotic tissues (hepatic stem cells, pancreatic stem cells, lung stem cells, renal stem cells, bone marrow stem cells, heart stem cells, spleen stem cells, uterine stem cells, skin stem cells.
- the “space” includes not only a void in the tissue but also a space where cells can expand and proliferate, for example, a space where pressure between cells is reduced, a flexible space, and the like.
- the composition of the present invention further includes a targeting agent for collagen-producing cells in the fibrotic tissue.
- a targeting agent for collagen-producing cells in the fibrotic tissue.
- a collagen-reducing substance that targets collagen-producing cells such as, but not limited to, a substance that inhibits production / secretion of extracellular matrix components, HGF or its production promoting substance, MMP or its production Promoters, TIMP inhibitors, TGF ⁇ production inhibitors, relaxin or production promoters thereof can be specifically delivered to collagen-producing cells as target cells, and the effect of the collagen-reducing substance used can be enhanced. it can.
- the targeting agent for collagen-producing cells is a retinoid.
- a retinoid targeting mechanism has not yet been fully elucidated, for example, a retinoid specifically bound to RBP (Retinol binding protein) is located on the cell surface of collagen-producing cells in fibrotic tissue. It can be taken up by the same cell via a receptor. It has been described in WO 2006/068232, JP-A 2009-221164, JP-A 2010-59124, and the like that a retinoid can function as a targeting agent for collagen-producing cells.
- RBP Retinol binding protein
- a retinoid is a member of a group of compounds with a skeleton in which four isoprenoid units are linked in a head-to-tail manner (G. P. Moss, “Biochemical Nomenclature and Related Documents,” 2nd Ed. Portland Press, pp. 247-251 (1992)), vitamin A is a general descriptor of retinoids that qualitatively shows the biological activity of retinol.
- the retinoid that can be used in the present invention is not particularly limited.
- retinol including all-trans retinol
- retinal retinoic acid (including tretinoin)
- ester of retinol and fatty acid aliphatic alcohol and retinoic acid
- retinoid derivatives such as esters, etretinate, isotretinoin, adapalene, acitretin, tazarotene, retinol palmitate, and vitamin A analogs such as fenretinide (4-HPR) and bexarotene.
- retinol, retinal, retinoic acid, esters of retinol with fatty acids (eg retinyl acetate, retinyl palmitate, retinyl stearate, and retinyl laurate) and esters of fatty alcohols with retinoic acid (Eg, ethyl retinoate) is preferred in terms of the efficiency of delivery of specific substances to collagen producing cells in fibrotic tissue. All isomers, including cis-trans of retinoids, are within the scope of the present invention.
- the retinoid may also be substituted with one or more substituents.
- the retinoid in the present invention includes not only an isolated state but also a retinoid in a state of being dissolved or mixed in a medium capable of dissolving or holding the same.
- composition of the present invention may be composed of only a collagen-reducing substance targeting collagen-producing cells as an active ingredient and a retinoid as a targeting agent, or may contain a carrier component other than these. But you can.
- the carrier component in the present embodiment is not particularly limited, and any of those known in the pharmaceutical and / or pharmaceutical field can be used, but at least a retinoid can be included or bound thereto. Those are preferred.
- Such components include lipids, phospholipids such as glycerophospholipids, sphingolipids such as sphingomyelin, sterols such as cholesterol, vegetable oils such as soybean oil and poppy oil, lecithins such as mineral oil and egg yolk lecithin, polymers, etc. However, it is not limited to these.
- liposomes for example, natural phospholipids such as lecithin, semisynthetic phospholipids such as dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), and dioleyl phosphatidylethanol Amine (DOPE), dilauroyl phosphatidylcholine (DLPC), cholesterol and the like are preferable.
- natural phospholipids such as lecithin
- semisynthetic phospholipids such as dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), and dioleyl phosphatidylethanol Amine (DOPE), dilauroyl phosphatidylcholine (DLPC), cholesterol and the like are preferable.
- Particularly preferred components include components that can avoid capture by the reticuloendothelial system, such as N- ( ⁇ -trimethylammonioacetyl) -didodecyl-D-glutamate chloride (TMAG), N, N ′, N ′′, N ′ ′′-tetramethyl-N, N ′, N ′′, N ′ ′′-tetrapalmitylspermine (TMTPS), 2,3-dioleyloxy-N- [2 (sperminecarboxamido) ethyl] -N , N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N- [1- (2,3-dioleyloxy) propyl] -N, N, N-trimethylammonium chloride (DOTMA), dioctadecyldimethyl Ammonium chloride (DODAC), didodecyl ammonium bromide (DDAB), 1,2-dioleyloxy-3-tri
- the carrier may have a specific three-dimensional structure. Examples of such a structure include, but are not limited to, a linear or branched linear structure, a film-like structure, and a spherical structure. Thus, the carrier may have any three-dimensional form such as, but not limited to, micelles, liposomes, emulsions, microspheres, nanospheres.
- Binding or inclusion of the retinoid and / or active ingredient to the carrier is also possible by binding or including the retinoid to the carrier by chemical and / or physical methods.
- the retinoid and / or active ingredient can be bound or included in the carrier by mixing the retinoid and / or active ingredient and the carrier component.
- the amount of retinoid in the composition of the present invention can be, for example, 0.01 to 1000 nmol / ⁇ l, preferably 0.1 to 100 nmol / ⁇ l.
- the amount of the active ingredient in the composition of the present invention is, for example, 1 to 10000 ng / ⁇ l, preferably 10 to 1000 ng / ⁇ l, or 1 to 1000000 ⁇ g / kg body weight, preferably 10 to 100000 ⁇ g / kg body weight. Is possible.
- the amount of retinoid and active ingredient may be outside the above range depending on the activity of these ingredients, the route of administration of the composition, the frequency of administration, the subject of administration, etc., but it is still within the scope of the present invention. .
- the binding or inclusion of the retinoid and / or active ingredient to the carrier may be performed before the active ingredient is loaded on the carrier, or may be performed by mixing the carrier component, the retinoid and the active ingredient simultaneously.
- the retinoid may be mixed with a carrier already loaded with an active ingredient. Therefore, the present invention also includes a step of binding a retinoid to any existing drug-binding carrier or drug-encapsulating carrier, for example, a liposome preparation such as DaunoXome (R) , Doxil, Caelyx (R) , Myocet (R) ,
- a liposome preparation such as DaunoXome (R) , Doxil, Caelyx (R) , Myocet (R)
- the present invention also relates to a method for producing a pharmaceutical composition for regenerating normal tissue from fibrotic tissue.
- the form of the composition of the present invention may be any form as long as the desired active ingredient can be delivered to the collagen-producing cells in the target fibrotic tissue, for example, without limitation, polymeric micelles, liposomes, emulsions, microparticles. Any form of spheres, nano-globules, etc. can be taken.
- the form of liposomes is preferred, and among these, cationic liposomes containing cationic lipids are particularly preferred.
- the molar ratio of retinoid to liposome-constituting lipid is preferably 8: 1 to 1: 4, more preferably considering the efficiency of binding or inclusion of the retinoid to the carrier. 4: 1 to 1: 2.
- composition of the present invention may contain the active ingredient inside, the active ingredient may adhere to the outside, or may be mixed with the active ingredient. Therefore, the composition of the present invention may take the form of a complex of liposome and active ingredient, that is, a lipoplex, and depending on the route of administration, drug release mode, etc., the composition may be a suitable material, for example, It may be coated with an enteric coating, a time-disintegrating material, or incorporated into a suitable drug release system.
- a retinoid When a retinoid is included as a targeting agent, it is present in the composition in a manner that functions as a targeting agent.
- functioning as a targeting agent means that a composition containing a retinoid reaches a collagen-producing cell in a fibrotic tissue that is a target cell more rapidly and / or in a larger amount than a composition containing no retinoid, and / or Or is incorporated, which is easily confirmed, for example, by adding a labeled or containing composition to the target cell culture and analyzing the location of the label after a predetermined time be able to. Structurally, for example, if the retinoid is at least partially exposed to the outside of the composition before reaching the target cell at the latest, the above requirement can be satisfied.
- Whether or not the retinoid is exposed to the outside of the composition is determined by contacting the composition with a substance that specifically binds to the retinoid, for example, retinol binding protein (RBP) and investigating the binding to the composition. Can be evaluated.
- a substance that specifically binds to the retinoid for example, retinol binding protein (RBP) and investigating the binding to the composition.
- RBP retinol binding protein
- the retinoid It is possible to at least partially expose the retinoid to the outside of the composition before reaching the target cell at the latest, for example, by adjusting the blending ratio of the retinoid and the carrier component.
- a lipid structure such as a liposome
- the lipid structure and a retinoid are complexed
- the lipid structure is first diluted in an aqueous solution, and then this is retinoided.
- the retinoid may be in a state dissolved in a solvent, for example, an organic solvent such as DMSO.
- the lipid structure means a structure having an arbitrary three-dimensional structure, for example, a linear shape, a film shape, a spherical shape, and the like, which includes lipid as a constituent component, and is not limited to liposomes, micelles. , Lipid microspheres, lipid nanoglobules, lipid emulsions and the like.
- the same targeting agent that targeted liposomes can be applied to other drug carriers, e.g. Zhao and Lee, Adv Drug Deliv Rev. 2004; 56 (8): 1193-204, Temming et al., Drug Resist Updat. 2005; 8 (6): 381-402.
- composition of the present invention may further contain a substance that reduces fibrosis stimulation as an active ingredient in addition to the collagen reducing substance, or may be used in combination with such a substance.
- substances that reduce fibrosis stimulation include, but are not limited to, antioxidants, blood circulation promoters, anti-inflammatory agents, antiviral agents, antibiotics, antiparasitic agents, liver protectants, antibacterial agents, apoptosis Inhibiting substances are included. These substances can be appropriately selected according to the target tissue and disease state.
- the composition of the present invention may contain a label.
- labeling By labeling, it becomes possible to monitor the success or failure of delivery to target cells and the increase / decrease of target cells, which is useful not only at the test / research level but also at the clinical level.
- the label is selected from any known to those skilled in the art, for example, any radioisotope, magnetic substance, substance that binds to the labeling substance (eg, antibody), fluorescent substance, fluorophore, chemiluminescent substance, enzyme, and the like. can do.
- the label may be attached to at least one of the components of the composition of the present invention, for example, when containing a retinoid as a targeting agent, one or more of the active component, the retinoid and the carrier component. It may be included in the composition as a separate component.
- “for collagen-producing cells in fibrotic tissue” or “for delivery of collagen-producing cells in fibrotic tissue” means that the collagen-producing cells in fibrotic tissue are suitable for use as target cells. Includes, for example, the ability to deliver substances to the same cell more rapidly, efficiently and / or in larger quantities than other cells, eg, normal cells.
- a carrier for collagen-producing cells in fibrotic tissue or a carrier for delivery of collagen-producing cells in fibrotic tissue has a collagen production cell in fibrotic tissue of 1.1 times or more, 1.2 times higher than other cells. Active ingredients can be delivered at rates and / or efficiencies that are more than double, 1.3 times, 1.5 times, 2 times, or even 3 times.
- the composition of the present invention can be used as a composition for collagen-producing cells in fibrotic tissue or for delivery of collagen-producing cells in fibrotic tissue by including a targeting agent for collagen-producing cells in fibrotic tissue.
- compositions of the present invention can be used as medicaments (ie, pharmaceutical compositions) and can be used in a variety of routes including both oral and parenteral, such as, without limitation, oral, enteral, intravenous, intramuscular. , Subcutaneous, topical, intrahepatic, intrabiliary, intrapulmonary, intratracheal, intratracheal, intrabronchial, intranasal, rectal, intraarterial, intraportal, intraventricular, intramedullary, intralymphatic, intralymphatic, intracerebral May be administered by routes such as internal, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, and intrauterine, and may be formulated into dosage forms suitable for each administration route.
- routes including both oral and parenteral, such as, without limitation, oral, enteral, intravenous, intramuscular.
- dosage forms suitable for oral administration include, but are not limited to, powders, granules, tablets, capsules, solutions, suspensions, emulsions, gels, syrups, etc.
- Suitable dosage forms include injections such as solution injections, suspension injections, emulsion injections, and injections prepared at the time of use.
- Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile solutions or suspensions.
- composition of the present invention may be supplied in any form, but from the viewpoint of storage stability, a form that can be prepared at the time of use, for example, a doctor and / or a pharmacist, a nurse at or near a medical site. Alternatively, it can be provided in a form that can be prepared by other paramedical or the like.
- the composition of the present invention is provided as one or more containers comprising at least one of the essential components thereof, and is used before use, for example, within 24 hours, preferably 3 hours before. Within, and more preferably just before use. In the preparation, reagents, solvents, dispensing devices and the like that are usually available at the place of preparation can be appropriately used.
- the present invention also provides a preparation kit for a composition
- a preparation kit for a composition comprising one or more containers containing the active ingredients and / or optionally targeting agents and carrier constituents, alone or in combination, and so on. It also relates to the necessary components of the composition provided in the form of a simple kit.
- the kit of the present invention may contain instructions on how to prepare and administer the composition of the present invention, and electronic recording media such as CD and DVD.
- the kit of the present invention may contain all of the components for completing the composition of the present invention, but may not necessarily contain all of the components. Therefore, the kit of the present invention may not contain reagents and solvents that are usually available at medical sites, experimental facilities, etc., such as sterile water, physiological saline, and glucose solution.
- the present invention further relates to a method for regenerating normal tissue from fibrotic tissue comprising the step of administering an effective amount of a composition or collagen-reducing substance of the present invention to a subject in need thereof.
- the effective amount is, for example, an amount that suppresses an increase in the amount of extracellular matrix such as collagen in fibrotic tissue, preferably an amount that reduces the amount of extracellular matrix, more preferably normal in fibrotic tissue. It is the amount that brings about the regeneration of the organization.
- the amount of extracellular matrix can be quantified by various methods, for example, without limitation, image analysis of a specially stained image of the extracellular matrix, measurement of an extracellular matrix marker, and the like.
- image analysis for example, for collagen, the amount of a collagen marker such as hydroxyproline is measured, or the tissue is subjected to collagen staining (for example, Masson-Trichrome staining, Azan staining, Sirius red staining, Elastica-Wangyson staining, etc.) and image analysis is performed.
- the amount can be quantified.
- the decrease rate of the extracellular matrix in the fibrotic tissue is, for example, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% compared to the case where the composition of the present invention is not administered.
- composition of the present invention when the composition of the present invention was not administered, not only when administration itself was not performed, but also a composition corresponding to the composition of the present invention, except that only the vehicle and no active ingredient were contained.
- the case where the composition of the invention contains a targeting agent includes the case where a composition corresponding to the composition of the invention is administered except for not containing the targeting agent (so-called negative control).
- regeneration of normal tissue can be evaluated by histological findings or by administering labeled stem cells to fibrotic tissue and following it up.
- the effective amount is preferably an amount that does not cause adverse effects exceeding the benefits of administration.
- Such an amount can be appropriately determined by an in vitro test using cultured cells or the like, or a test in a model animal such as a mouse, rat, dog or pig, and such a test method is well known to those skilled in the art. .
- the dose of the drug used in the method of the present invention is known to those skilled in the art or can be appropriately determined by the above-described test or the like.
- Fibrosis model animals include carbon tetrachloride (CCl 4 ), porcine serum, dimethylnitrosamine (DMN), methionine-choline deficient diet (MCDD), concanavalin A (Con A), cirrhosis model due to bile duct ligation, bleomycin ( Various models such as pulmonary fibrosis models such as BLM), pancreatic fibrosis models such as dibutyltin dichloride, and myelofibrosis models such as thrombopoietin (TPO) transgenic mice (Leukemia Research 29: 761-769, 2005) Is available.
- CCl 4 carbon tetrachloride
- DN dimethylnitrosamine
- MCDD methionine-choline deficient diet
- Con A concanavalin A
- cirrhosis model due to bile duct ligation bleomycin
- Various models such as pulmonary fibrosis models such as BLM), pancreatic
- compositions or collagen-reducing substance administered in the methods of the present invention can vary depending on various conditions related to the subject requiring treatment, such as severity of symptoms, general health of the subject, age, weight, gender of the subject. , Diet, timing and frequency of administration, medication used in combination, responsiveness to treatment, compliance with treatment, and the like.
- Administration routes include various routes including both oral and parenteral, such as oral, enteral, intravenous, intramuscular, subcutaneous, topical, intrahepatic, intrabiliary, intrapulmonary, intratracheal, intratracheal, Intrabronchial, nasal, rectal, intraarterial, portal vein, ventricular, intramedullary, intralymphatic, intralymphatic, intracerebral, intrathecal, intraventricular, transmucosal, transdermal, intranasal, abdominal cavity Routes such as internal and intrauterine are included. The frequency of administration varies depending on the properties of the composition used and the conditions of the subject as described above.
- the term “subject” means any living individual, preferably an animal, more preferably a mammal, and more preferably a human individual.
- the subject may be healthy or may have some disease, but typically means a subject having a fibrotic tissue or having a risk of fibrosis of the tissue. Examples of such a subject include, but are not limited to, a subject suffering from or having a risk of suffering from the above organ fibrosis, a subject having received or at risk of receiving fibrosis stimulation, and the like.
- the present invention further relates to a method for regenerating normal tissue from fibrotic tissue, comprising the step of reducing collagen in the fibrotic tissue and / or creating a space for cell growth and differentiation in the fibrotic tissue.
- the reduction of collagen in the fibrotic tissue and the generation of a space for cell proliferation / differentiation can be performed by administering the composition of the present invention or the above-described collagen reducing substance to the fibrotic tissue.
- Example 1 Preparation of VA-lip siRNA
- siRNA siRNA targeting the base sequence of gp46 GenBank Accession No. M69246
- a rat Homologue of human HSP47 a common molecular chaperone of collagen (types I to IV) (Science, Sapporo, Japan)
- the following sense strand and antisense strand were used.
- siRNArandom (sometimes referred to as siRNA scramble).
- C CGAUUCCGCUAGACCGGCUUCAUUGCAG (sense strand siRNA, SEQ ID NO: 3)
- D GCAAUGAAGCCGGUCUAGCGAAUCGAU (antisense strand siRNA, SEQ ID NO: 4)
- a sense strand with 6'-carboxyfluorescein (6-FAM) or fluorescein isothiocyanate (FITC) bound to the 5 'end was used. These sequences were confirmed to have no homology with other known rat mRNAs in BLAST searches.
- VA-lip siRNA As cationic lipids, O, O′-ditetradecanoyl-N- ( ⁇ -trimethylammonioacetyl) diethanolamine chloride (DC-6-14), cholesterol and dioleylphosphatidylethanol Cationic liposomes (LipoTrust) containing amine (DOPE) in a molar ratio of 4: 3: 3 were purchased from Hokkaido System Science (Sapporo, Japan). Liposomes were prepared at a concentration of 1 mM (DC-6-14) by adding double-distilled water (DDW) under stirring conditions to the lyophilized lipid mixture prior to use.
- DC-6-14 O, O′-ditetradecanoyl-N- ( ⁇ -trimethylammonioacetyl) diethanolamine chloride (DC-6-14), cholesterol and dioleylphosphatidylethanol Cationic liposomes (LipoTrust) containing amine (DOPE) in a molar ratio of 4: 3: 3 were purchased from
- VA-bound liposomes 200 nmol of vitamin A (retinol, Sigma, USA) dissolved in DMSO and liposome suspension (100 nmol as DC-6-14) were stirred at 25 ° C. in a 1.5 ml tube. Mixed.
- VA-bound liposomes carrying siRNAgp46 (VA-lip-siRNAgp46)
- siRNAgp46 solution (580 pmol / ml in DDW) was added to the retinol-bound liposome solution at room temperature with stirring.
- the molar ratio of siRNA to DC-6-14 was 1:11.
- VA-lip siRNA was reconstituted with phosphate buffered saline (PBS).
- Example 2 Regenerative treatment experiment with liver fibrosis model rats
- Liver fibrosis model rats were ligated to the common bile duct against male SD rats (weight 150-200 g) (Slc Japan, Shizuoka, Japan). The individuals on the 28th day after ligation were subjected to this experiment.
- cholestasis occurs due to ligation of the common bile duct, and the liver tissue is continuously exposed to fibrosis stimulation.
- GFP-labeled rat hepatic stem cells were collected from the livers of 4-week-old GFP gene-introduced rats (Slc Japan). First, an EGTA solution and a collagenase solution were perfused into a GFP gene-introduced rat, and then the liver was collected. The collected liver was cut into small pieces, and then filtered through a cell strainer (pore size: 100 ⁇ m). Hank's balanced salt solution (HBSS) + 0.25% bovine serum albumin (BSA) solution was added to the obtained cell suspension and centrifuged at 4 ° C. and 500 rpm for 2 minutes.
- HBSS Hank's balanced salt solution
- BSA bovine serum albumin
- MACS® Magnetic Activating Cell Sorting buffer (Miltenyi Biotec, Auburn, CA, USA) was added to the precipitate and mixed. After counting the number of cells, MACS (R) was performed using FITC-conjugated mouse anti-CD45 antibody (BD Pharmingen), rabbit polyclonal anti-CD133 antibody (Abcam) and mouse monoclonal anti-EpCAM antibody (Santa Cruz), and CD133 positive, EpCAM Positive and CD45 negative cells were collected and used as rat hepatic stem cells in this experiment.
- MACS® Magnetic Activating Cell Sorting
- mice monoclonal anti- ⁇ smooth muscle actin ( ⁇ -SMA) antibody Sigma
- mouse monoclonal anti-glial fibrillary acidic protein (GFAP) antibody Sigma
- rabbit polyclonal anti-albumin antibody MP Biomedicals
- mouse monoclonal anti-CK19 antibody Novocastra
- mouse monoclonal anti-vascular endothelial cadherin ve-CAD, Vascular Endothelial Cadherin
- Alexa555-labeled goat anti-mouse IgG antibody or Alexa555-labeled goat anti-rabbit IgG antibody both Invitrogen was reacted at room temperature for 60 minutes. After washing with PBS, then filled with ProLong (R) Gold with DAPI ( Invitrogen), it was observed by the fluorescence microscope. A part of the section was reacted with ⁇ -SMA antibody (Dako), then colored with diaminobenzidine (DAB) instead of reaction with goat anti-rabbit antibody, and further nuclear stained with hematoxylin.
- FIG. 1 shows the appearance of a liver collected from a test rat and an Azan-stained image of a representative section thereof.
- the liver was atrophied, the surface was irregular, the accumulation of extracellular matrix stained in blue in the Azan-stained image in the tissue was extensive, and the liver lobule structure was also disordered It was.
- the surface was smooth, the accumulation of extracellular matrix in the tissue was hardly observed, and the VA-lip siRNA scramble administration group The fibrosis area was clearly reduced compared to.
- FIG. 2 is a DAB-stained image of ⁇ -SMA antibody.
- the blue part represents the nucleus stained with hematoxylin, and the dark brown part is the ⁇ -SMA positive region.
- ⁇ -SMA is known as a marker of activated stellate cells, and it is considered that activated stellate cells are present in the ⁇ -SMA positive region.
- VA-lip siRNAgp46 administration group a significant decrease in activated stellate cells was seen as compared with VA-lip siRNA scramble.
- FIG. 3 is a fluorescence image of DAPI and GFP at the site of transplantation of GFP-labeled hepatic stem cells.
- GFP coloration was observed in an area of about 80%, whereas in the VA-lip siRNA scramble administration group, it was hardly observed.
- FIG. 4 shows a bright-field image and a GFP fluorescence image of the GFP-labeled hepatic stem cell transplantation site.
- the shape of the cell is blurred due to the deposition of the extracellular matrix, especially around the blood vessels, and the sinusoids also run randomly, whereas in the VA-lip siRNA gp 46 administration group, it is clear Cell shape and sinusoidal structure running radially from the central vein were seen.
- the VA-lip siRNA scramble administration group no GFP coloration was observed, whereas in the VA-lip siRNAgp46 administration group, GFP coloration was observed throughout the tissue.
- FIG. 5 compares the DAPI and GFP fluorescence images with the GFAP antibody-stained fluorescence images in the VA-lip siRNAgp46 administration group (FIG. 5A is 200 times magnification, and FIG. 5B is 400 times magnification).
- GFAP is a protein known as a marker for resting hepatic stellate cells. Cells expressing GFAP did not express GFP.
- FIG. 6 is a comparison of DAPI and GFP fluorescence images with an ⁇ -SMA antibody fluorescence staining image at a magnification of 200 ⁇ in the VA-lip siRNAgp46 administration group. Cells expressing ⁇ -SMA did not express GFP.
- the results in FIGS. 5 and 6 suggest that hepatic stellate cells are not derived from hepatic stem cells.
- FIG. 7 compares the DAPI and GFP fluorescence images with the albumin antibody fluorescence staining image at a magnification of 200 times in the VA-lip siRNAgp46 administration group.
- Albumin is a marker of hepatocytes, but many cells expressing GFP expressed albumin.
- FIG. 8 compares the DAPI and GFP fluorescence images with the CK19 antibody fluorescence staining image at a magnification of 200 times in the VA-lip siRNAgp46 administration group.
- CK19 is a marker for bile duct epithelial cells, but CK19 positive cells constituting the bile duct expressed GFP.
- FIG. 9 compares the DAPI and GFP fluorescence images with the ve-CAD antibody fluorescence images in the VA-lip siRNAgp46 administration group (FIG. 9A is 200 times magnification, and FIG. 9B is 400 times magnification).
- Ve-CAD is known as a marker for vascular epithelial cells, and in some of the cells expressing GFP, cells expressing ve-CAD were observed.
- FIG. 10 is a comparison of a DAPI / GFP fluorescence image and a fluorescence staining image with an albumin antibody at a magnification of 200 ⁇ at a site where cells were not transplanted in the VA-lip siRNAgp46 administration group. No GFP-expressing cells were observed at the site where cells were not transplanted.
- VA-lip siRNAgp46 causes hepatic stem cells to become hepatocytes, bile duct epithelial cells and It has been shown that normal liver tissue is regenerated by differentiating into vascular epithelial cells. That is, it has been clarified that treatment with VA-lip siRNAgp46 administration induces not only healing of liver fibrosis but also liver regeneration. Moreover, the fact that hepatic stem cells could not be detected in the VA-lip siRNA scramble administration group (FIG. 3) suggests that the reduction of the fibrosis area by VA-lip siRNAgp46 is deeply involved in the proliferation and differentiation of hepatic stem cells. is doing.
- Example 3 Stellar cell-specific delivery by VA Isolation of rat pancreatic stellate cells (PSC) Rat pancreatic stellate cells (PSC) were subjected to concentration gradient centrifugation according to a previous report (Apte et al. Gut 1998; 43: 128-133). Isolated using separation methods. Purity was assayed by microscopic observation, endogenous VA autofluorescence, and immunocytochemistry using a monoclonal antibody (1:25, Dako) to the muscle actin cross-linking protein desmin. Cell viability was assayed by trypan blue excretion. Both cell purity and viability were above 95%. The cells were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum (FBS) in a humidified environment of 37 ° C. and 95% air / 5% CO 2 .
- IMDM Iscove's modified Dulbecco's medium
- FBS
- VA-lip siRNAgp46-FAM Rat pPSCs primary pancreatic stellate cells, primary PSC
- VA-lip siRNAgp46-FAM or Lip siRNAgp46-FAM was added to the cells to a final siRNA concentration of 50 nM.
- the cells were cultured for 30 minutes in DMEM containing 10% FBS, and the medium was replaced with fresh medium. At 30 minutes and 2 hours after treatment, the cells were washed 3 times with PBS and fixed with 4% paraformaldehyde for 15 minutes at 25 ° C.
- PSC was treated with VA-lip siRNAgp46 (50 nM) for 30 minutes, cultured for 24 hours, 48 hours, 72 hours and 96 hours, and then extracted with VA.
- -Western blotting experiments were performed in the same manner as described above, with 30 minutes after treatment with lip-siRNArandom (50 nM).
- Rat pPSCs were seeded in 6-well tissue culture plates at a density of 5 ⁇ 10 4 cells / well in DMEM containing 10% FBS. After 24 hours of culture, rat pPSCs were treated with VA-lip siRNAgp46 (50 nM siRNA) or VA-lip siRNArandom (50 nM siRNA). Cells were cultured for 30 minutes in DMEM containing 10% FBS, after which the medium was replaced with fresh medium. 72 hours after treatment, cells were washed 3 times with PBS and collagen deposited in wells was stained with Sirius red (Biocolor, Harbor, UK) according to previous reports (Williams et al. Gut 2001; 49: 577-583). . Unbound dye was washed away and the bound complex was dissolved in 0.5% sodium hydroxide. Collagen was quantified by spectrophotometric analysis at 540 nm and results were expressed as a percentage of the untreated control.
- FIG. 11 is a fluorescence image showing the intracellular distribution of FAM-labeled siRNA.
- the two on the left are fluorescence images of PSC treated with VA-lip siRNAgp46-FAM, and the two on the right are fluorescence images of PSC treated with Lip siRNAgp46-FAM.
- the upper two images are images 30 minutes after the treatment, and the lower two images are images 2 hours after the treatment.
- VA-lip siRNAgp46-FAM green fluorescence of a granular pattern of FAM that was blurred in the cytoplasm was observed 30 minutes after the treatment, and a darker granular pattern was observed in the perinuclear region 2 hours after the treatment.
- no green fluorescence was observed 30 minutes after treatment, and fluorescence around the nucleus 2 hours after treatment was faint.
- FIG. 12 is a graph showing the results of FACS analysis.
- the results of the untreated group, the Lip siRNAgp46-FAM treated group, the VA-lip siRNAgp46-FAM treated group, the VA-lip siRNAgp46-FAM + RBP antibody treated group, and the Lip siRNAgp46-FAM + RBP antibody treated group are shown in order from the top.
- the fluorescence intensity was suppressed to the same level as in the Lip siRNAgp46-FAM treatment group compared to the VA-lip siRNAgp46-FAM treatment group. This suggests that VA-lip siRNAgp46 incorporation into PSC is RBP receptor-mediated.
- FIG. 13A shows the results of Western blotting showing the difference in inhibitory effect depending on the concentration.
- gp46 expression suppression was observed depending on the concentration of VA-lip siRNAgp46, and almost completely suppressed at 50 nM, whereas in VA-lip siRNArand and Lip siRNAgp46 Expression suppression was not observed.
- FIG. 13B represents the results of Western blotting confirming the duration of the inhibitory effect.
- FIG. 14 is a graph quantifying the amount of collagen produced after 72 hours in untreated cells and cells treated with VA-lip siRNAgp46 and VA-lip siRNArandom, respectively. When treated with VA-lip siRNAgp46, significant suppression of collagen production was confirmed as compared to untreated cells and cells treated with VA-lip siRNArandom.
- VA-lip siRNAgp46 is specifically incorporated into PSC by RBP receptor-mediated uptake and suppresses the expression of gp46, and as a result, remarkably suppresses the production of collagen. Recognize. This suggests that VA-lip siRNAgp46 can reduce collagen in the pancreas affected by pancreatic fibrosis.
- Example 4 Regenerative treatment experiment in pancreatic fibrosis model rat
- a male Lewis rat having a body weight of 150 to 200 g was used.
- DBTC dibutyltin dichloride
- DMSO dimethyl sulfoxide
- VA-lip siRNAgp46-FITC In vivo localization of VA-lip siRNAgp46-FITC in rat pancreas and other tissues
- VA-lip siRNAgp46-FITC or Lip siRNAgp46-FITC was administered from the tail vein. Administration was performed under normal pressure, and 0.75 mg / kg siRNA was administered three times every other day. Twenty-four hours after the last dose, rats were sacrificed by saline perfusion and the pancreas and other organs (liver, lung, spleen and retina) were collected.
- Example 3 shows protein extracts from the pancreas at 0, 1, 2, 3, and 4 days after intravenous administration of VA-lip siRNAgp46 in order to evaluate the duration of expression suppression by siRNAgp46 in vivo. .
- Western blotting was performed as in (4).
- Immunohistochemical staining is performed by the dextran polymer method using monoclonal anti- ⁇ -SMA antibody (1: 1000, Sigma) and Envision Kit (Dako), followed by color development by DAB (Wako Pure Chemical Industries, Osaka, Japan) Nuclear staining with gil-hematoxylin solution (Wako Pure Chemical Industries) was performed.
- DAB Wired Chemical Industries, Osaka, Japan
- Nuclear staining with gil-hematoxylin solution was performed.
- six low-power fields ⁇ 100 were randomly selected for each rat pancreas section and microscopic (Axioplan 2; Carl Observed by Zeiss, Inc).
- Digital images were taken with a video recording system using a digital TV camera system (Axiocam High Resolution color, Carl Zeiss, Inc.).
- An automated software analysis program (KS400, Carl Zeiss, Inc.) was used to determine the percentage of areas stained with Azan-Mallory and ⁇ -SMA in the digital micrograph.
- hydroxyproline assay The hydroxyproline content was determined by the Weidenbach method according to the previous report (Weidenbach et al. Digestion 1997; 58: 50-57). Briefly, the pancreatic cell debris was centrifuged at 3000 rpm for 15 minutes, the pellet was completely hydrolyzed in 6N HCl for 16 hours at 96 ° C., and the pH was adjusted to 6.5-7.5, It was centrifuged again (3000 rpm for 15 minutes).
- Collagenase activity in pancreatic cell debris was measured by a modified method of a previous report (Iredale et al. J. Clin. Invest. 1998; 102: 538-549). Briefly, pancreas collected from wild type rats and pancreatic fibrosis model rats and frozen in liquid nitrogen were serine- and thiol-protease inhibitors (PMSF 0.1 mM, leupeptin 10 ⁇ M, pepstatin A 10 ⁇ M, aprotinin 25 ⁇ g / ml).
- siRNAgp46-FITC by macrophages Suggests non-specific uptake of.
- the retina is negative for FITC staining (FIG. 15F), which is consistent with findings using VA-lip siRNAgp46-FAM in cirrhosis. This is probably because the eyeball has built an independent system due to the low permeability of the blood-retinal barrier.
- DBTC-treated rats that received 10 doses of VA-lip siRNAgp46 were evaluated by Azan-Mallory staining (FIG. 17A).
- the fibrosis area determined by computer image analysis was significantly reduced in the VA-lip siRNAgp46-administered group compared to the control specimen (P ⁇ 0.01) (FIG. 17B). This result is consistent with the data (FIG. 17C) showing clear suppression of hydroxyproline in the pancreas of the VA-lip siRNAgp46 administration group.
- VA-lip siRNAgp46 administration suggests that collagenase derived from inflammatory cells and PSC itself may be involved in the improvement of fibrosis following suppression of new collagen secretion from PSC
- the table below shows the results of measurement of collagenase activity in pancreatic cell lysates of wild type rats and DBTC-treated rats treated with VA-lip siRNAgp46.
- VA-lip siRNAgp46 specifically siRNAgp46 is taken up into activated pancreatic stellate cells (aPSC) and suppresses the expression of gp46, resulting in the secretion of collagen from aPSC. It can be seen that suppressing it exerts a remarkable effect in improving pancreatic fibrosis. Furthermore, a significant decrease in aPSC was observed, probably due to a decrease in collagen secretion. And notably, treatment with VA-lip siRNAgp46 has been demonstrated to induce not only improvement of pancreatic fibrosis but also regeneration of pancreatic tissue. When taken together with the results in Example 2 above, these results indicate that normal tissue can be regenerated from fibrotic tissue non-specifically by reducing collagen accumulated in fibrotic tissue.
- Example 5 Importance of space for stem cell proliferation and differentiation Activated hepatic stellate cells (aHSC) were co-cultured with hepatic progenitor cells of various densities, and the influence of the presence or absence of the space around the cells on the differentiation of hepatic progenitor cells was examined. .
- aHSC Activated hepatic stellate cells
- the GFP-labeled rat hepatic stem cells obtained in Example 2 (2) above were used, and as the aHSCs, HSCs collected from SD rats were cultured and passaged once. aHSC was collected and cultured as follows.
- HBSS + 0.25% BSA solution was added to the obtained cell suspension and centrifuged at 4 ° C. and 500 rpm for 2 minutes. The supernatant was collected and centrifuged at 4 ° C. and 1300 rpm for 5 minutes. After removing the supernatant, HBSS + 0.25% BSA solution was added, and 28.7% Nycodenz solution (Axis Shield, Oslo, Norway) was added and mixed so that the concentration of Nycodenz was 13.2%.
- HBSS + 0.25% BSA solution After overlaying HBSS + 0.25% BSA solution, it was centrifuged at 1400 ⁇ g for 20 minutes at 4 ° C. After centrifugation, the intermediate layer was collected and cultured for 5 days using Dulbecco's Modified Eagle's medium (DMEM) + 10% fetal bovine serum (FBS) medium. Passage was performed on the fifth day of culture, and the cells were used in this experiment.
- DMEM Dulbecco's Modified Eagle's medium
- FBS fetal bovine serum
- AHSC was seeded at a density of 5 ⁇ 10 4 cells / well on a cell culture insert (pore size 0.4 ⁇ m, BD Falcon, Franklin Lakes, NJ, USA), and DMEM + 10 at 37 ° C. and 5% CO 2 in an incubator.
- the cells were cultured with% FBS for 48 hours. 2 days after aHSC seeding, 1 ⁇ 10 4 cells / well (low density) in a 24-well plate (BD Falcon) containing a cover glass (IWAKI, Tokyo, Japan) coated with type I collagen of hepatic progenitor cells or Seeding was performed at a density of 5 ⁇ 10 5 cells / well (confluent).
- the cell culture insert containing aHSC was inserted into a well of a 24-well plate and co-cultured in an incubator at 37 ° C. and 5% CO 2 for 10 days (as a medium, DME / F12 (Dulbecco's Modified Eagle's Medium / Nutrient F-12 Ham) + 10% FBS + ITS (using 10 mg / l insulin, 5.5 mg / l transferrin, 0.67 ⁇ g / l selenium) +0.1 ⁇ M dexamethasone + 10 mM nicotinamide + 50 ⁇ g / ml ⁇ -mercaptoethanol + 2 mM L-glutamine + 5 mM Hepes) .
- a medium DME / F12 (Dulbecco's Modified Eagle's Medium / Nutrient F-12 Ham) + 10% FBS + ITS (using 10 mg / l insulin, 5.5 mg / l transferrin, 0.67 ⁇ g / l se
- activated stellate cells induce proliferation / differentiation of stem cells, and the presence or absence of physical space around the stem cells has an important influence on the proliferation / differentiation of stem cells.
- the collagen tissue reduces the fibrous tissue in the fibrotic tissue and creates a space around the stem cell. As a result, the stem cell grows and differentiates, and the normal tissue is regenerated. Is shown.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
また、組織の線維化には、ウイルス感染、飲酒、薬物などに由来する線維症などの、病因が明確で、その除去が可能なものばかりでなく、直接的な病因が不明な線維症、例えば、特発性肝硬変、特発性肺線維症、特発性骨髄線維症など、または、直接的な病因は分かっているが、その病因の原因が不明なものや、除去困難なもの、例えば、原発性胆汁性肝硬変、非アルコール性脂肪肝炎(NASH)由来の肝線維症、原発性硬化性胆管炎なども含まれる。このような病因の除去が困難な線維化が存在する組織は、絶えず線維化刺激にさらされている状態にあるが、かかる線維化組織において病的な細胞外マトリックスの蓄積を減少させ得ることも、ましてや組織を再生し得ることもこれまで全く知られていなかった。
したがって、本発明は以下に関する。
(1)コラーゲン低減物質を含む、線維化組織から正常組織を再生するための医薬組成物。
(2)コラーゲン低減物質が、コラーゲン産生細胞によるコラーゲン産生を抑制する物質、コラーゲンの分解を促進する物質、およびコラーゲン分解阻害物質を抑制する物質からなる群から選択される、上記(1)に記載の医薬組成物。
(3)線維化組織におけるコラーゲン産生細胞に対する標的化剤をさらに含む、上記(1)または(2)に記載の医薬組成物。
(4)標的化剤がレチノイドである、上記(3)に記載の医薬組成物。
(5)線維化組織が、線維化刺激を継続的に受けている、上記(1)~(4)のいずれかに記載の医薬組成物。
(6)線維化組織に蓄積されたコラーゲンが低減されて生成される、幹細胞の増殖・分化用のスペースにおいて、線維化組織から正常組織を再生するための、上記(1)~(5)のいずれかに記載の医薬組成物。
(8)コラーゲンの分解を促進する物質がコラゲナーゼまたはその産生促進物質である、上記(2)~(6)のいずれかに記載の医薬組成物。
(9)コラーゲン分解阻害物質を抑制する物質がTIMP阻害物質である、上記(2)~(6)のいずれかに記載の医薬組成物。
また、本発明により、線維化刺激に継続的にさらされている線維化組織の治療が可能となり、従来有効な治療法が存在しなかった線維化疾患や、臓器移植しか治療法がなかった線維化疾患を含むあらゆる線維化疾患の内科的治療が実現するため、医療および獣医療に対して多大な貢献が期待できる。
本発明において、「コラーゲン低減物質」とは、組織に蓄積したコラーゲンの量を低減し得る任意の物質を意味する。特定の理論にとらわれることを意図するわけではないが、線維化組織におけるコラーゲン蓄積は、コラーゲンの産生と分解とのバランスが産生側に偏ることが一因と考えられているため、コラーゲン低減物質は、コラーゲンの産生を抑制する物質ばかりでなく、コラーゲンの分解を促進する物質や、同物質を阻害する物質を抑制する物質をも含み得る。したがって、コラーゲン低減物質としては、限定することなく、例えば、コラーゲン産生細胞によるコラーゲン産生を抑制する物質、コラーゲンの分解を促進する物質、コラーゲン分解阻害物質を抑制する物質等が挙げられる。本発明におけるコラーゲンは特に限定されないが、線維化に関与するコラーゲン、例えば、I、III、V型コラーゲンなどが好ましく、線維化組織に最も多量に存在するI型コラーゲンが特に好ましい。
PPARγリガンドとしては、限定することなく、例えば、15-デオキシ-Δ12,14-プロスタグランジンJ2、ニトロリノール酸、酸化LDL(Low density lipoprotein)、長鎖脂肪酸、エイコサノイドといった内因性リガンドや、トログリタゾン、ピオグリタゾン、ロシグリタゾン、バラグリタゾン、リボグリタゾン等のチアゾリジンジオン系薬剤、非ステロイド性抗炎症薬といった外因性リガンドなどが挙げられる。
PDGF阻害物質としては、限定することなく、例えば、抗PDGF抗体などのPDGF活性阻害物質や、PDGFに対するRNAi分子、リボザイム、アンチセンス核酸などのPDGF産生阻害物質、これらを発現するベクター、およびこれらで形質転換された細胞等が挙げられる。
アポトーシス誘導剤としては、限定することなく、例えば、compound 861、グリオトキシン、アトルバスタチンなどが挙げられる。
本発明の一態様において、正常組織の再生は、線維化組織に蓄積されたコラーゲンの低減により生成されたスペースにおいて、幹細胞が増殖・分化することにより生じるものであってもよい。したがって、本発明の一態様は、線維化組織に蓄積されたコラーゲンが低減されて生成される、幹細胞の増殖・分化用のスペースにおいて、線維化組織から正常組織を再生するための上記医薬組成物に関する。ここで、幹細胞には、限定されずに、例えば、線維化した組織に本来存在するもの(肝幹細胞、膵幹細胞、肺幹細胞、腎幹細胞、骨髄幹細胞、心臓幹細胞、脾臓幹細胞、子宮幹細胞、皮膚幹細胞、乳腺幹細胞、腸管幹細胞、間葉系幹細胞など)や、体内の別の場所から移動してきたもの、さらには治療的に投与したもの等が含まれる。また、「スペース」は、組織内の空隙のみならず、細胞が拡大・増殖し得る余地のある空間、例えば、細胞間の圧力が低減された空間や、柔軟性を有する空間などを含む。
本発明の一態様において、コラーゲン産生細胞に対する標的化剤はレチノイドである。レチノイドによる標的化機構は未だ完全には解明されていないが、例えば、RBP(Retinol binding protein)と特異的に結合したレチノイドが、線維化組織におけるコラーゲン産生細胞の細胞表面上に位置するある種のレセプターを介して同細胞に取り込まれることが考えられる。レチノイドがコラーゲン産生細胞への標的化剤として機能し得ることは、WO 2006/068232、特開2009-221164、特開2010-59124等に記載されている。
レチノイドのシス-トランスを含む異性体全ては、本発明の範囲内に入る。レチノイドはまた1または2以上の置換基で置換されることもある。本発明におけるレチノイドは、単離された状態のものはもちろんのこと、これを溶解または保持することができる媒体に溶解または混合した状態のレチノイドをも含む。
このような成分としては、脂質、例えば、グリセロリン脂質などのリン脂質、スフィンゴミエリンなどのスフィンゴ脂質、コレステロールなどのステロール、大豆油、ケシ油などの植物油、鉱油、卵黄レシチンなどのレシチン類、ポリマー等が挙げられるが、これらに限定されない。このうち、リポソームを構成し得るもの、例えば、レシチンなどの天然リン脂質、ジミリストイルホスファチジルコリン(DMPC)、ジパルミトイルホスファチジルコリン(DPPC)、ジステアロイルホスファチジルコリン(DSPC)などの半合成リン脂質、ジオレイルホスファチジルエタノールアミン(DOPE)、ジラウロイルホスファチジルコリン(DLPC)、コレステロールなどが好ましい。
上記担体は、特定の3次元構造を有してもよい。かかる構造としては、限定されずに、直鎖状または分枝状の線状構造、フィルム状構造、球状構造などが挙げられる。したがって、担体は、限定されずに、ミセル、リポソーム、エマルジョン、微小球、ナノ小球などの任意の3次元形態を有してもよい。
例えば、経口投与に適した剤形としては、限定することなく、散剤、顆粒剤、錠剤、カプセル剤、液剤、懸濁剤、乳剤、ゲル剤、シロップ剤などが挙げられ、また非経口投与に適した剤形としては、溶液性注射剤、懸濁性注射剤、乳濁性注射剤、用時調製型注射剤などの注射剤が挙げられる。非経口投与用製剤は、水性または非水性の等張性無菌溶液または懸濁液の形態であることができる。
投与経路としては、経口および非経口の両方を包含する種々の経路、例えば、経口、経腸、静脈内、筋肉内、皮下、局所、肝内、胆管内、肺内、気道内、気管内、気管支内、経鼻、直腸内、動脈内、門脈内、心室内、骨髄内、リンパ節内、リンパ管内、脳内、髄液腔内、脳室内、経粘膜、経皮、鼻内、腹腔内および子宮内等の経路が含まれる。
投与頻度は、用いる組成物の性状や、上記のような対象の条件によって異なるが、例えば、1日多数回(すなわち1日2、3、4回または5回以上)、1日1回、数日毎(すなわち2、3、4、5、6、7日毎など)、1週間に数回(例えば、1週間に2、3、4回など)、1週間毎、数週間毎(すなわち2、3、4週間毎など)であってもよい。
本方法において、線維化組織におけるコラーゲンの低減および細胞増殖・分化用のスペースの生成は、本発明の組成物または上述のコラーゲン低減物質を線維化組織に投与することにより行うことができる。
(1)siRNAの調製
コラーゲン(I~IV型)の共通分子シャペロンであるヒトHSP47のラットホモログ、gp46(GenBank Accession No. M69246)の塩基配列を標的とするsiRNA(北海道システム・サイエンス, Sapporo, Japan)のセンス鎖およびアンチセンス鎖は以下のものを用いた。
A:GUUCCACCAUAAGAUGGUAGACAACAG(gp46の塩基配列上の第757塩基から始まるセンス鎖siRNA、配列番号1)
B:GUUGUCUACCAUCUUAUGGUGGAACAU(アンチセンス鎖siRNA、配列番号2)
C:CGAUUCGCUAGACCGGCUUCAUUGCAG(センス鎖siRNA、配列番号3)
D:GCAAUGAAGCCGGUCUAGCGAAUCGAU(アンチセンス鎖siRNA、配列番号4)
カチオン性脂質として、O,O’-ジテトラデカノイル-N-(α-トリメチルアンモニオアセチル)ジエタノールアミンクロライド(DC-6-14)、コレステロールおよびジオレイルホスファチジルエタノールアミン(DOPE)を4:3:3のモル比で含むカチオン性リポソーム(LipoTrust)を北海道システム・サイエンス(Sapporo, Japan)から購入した。リポソームは、使用前に、凍結乾燥した脂質混合物に攪拌条件下で再蒸留水(DDW)を添加することによって、1mM(DC-6-14)の濃度で調製した。VA結合リポソームを調製するため、DMSOに溶解した200nmolのビタミンA(レチノール、Sigma, USA)をリポソーム懸濁液(DC-6-14として100nmol)と、1.5mlチューブ中で攪拌しながら25℃で混合した。siRNAgp46を担持するVA結合リポソーム(VA-lip-siRNAgp46)を調製するため、siRNAgp46溶液(DDW中に580pmol/ml)を、レチノール結合リポソーム溶液に攪拌しながら室温下で添加した。siRNAとDC-6-14とのモル比は1:11であった。in vitroでの使用に望ましい用量を得るため、VA-lip siRNAをリン酸緩衝生理食塩水(PBS)で再構成した。
(1)肝線維化モデルラットの作製
肝線維化モデルラットは、雄SDラット(体重150~200g)(Slc Japan, Shizuoka, Japan)に対して総胆管結紮を施して作製し、結紮後28日目の個体を本実験に供した。本モデルラットにおいては、総胆管結紮により胆汁の鬱滞が生じ、肝組織が線維化刺激に継続的にさらされた状態となる。
GFP標識ラット肝幹細胞は、4週齢のGFP遺伝子導入ラット(Slc Japan)の肝臓より採取した。まず、GFP遺伝子導入ラットにEGTA溶液およびコラゲナーゼ溶液を灌流した後、肝臓を採取し、採取した肝臓を細切した後、セルストレーナー(孔径100μm)で濾過した。得られた細胞懸濁液にハンクス平衡塩液(HBSS)+0.25%ウシ血清アルブミン(BSA)溶液を加えて、4℃、500rpmで2分間遠心した。上清を採取して、4℃、1300rpmで5分間遠心を行った。上清を除去した後、沈殿に対してMACS(R)(Magnetic Activating Cell Sorting)バッファ(Miltenyi Biotec, Auburn, CA, USA)を加えて混合した。細胞数を数えた後、FITC結合マウス抗CD45抗体(BD Pharmingen)、ウサギポリクローナル抗CD133抗体(Abcam)およびマウスモノクローナル抗EpCAM抗体(Santa Cruz)を用いてMACS(R)を行い、CD133陽性、EpCAM陽性、CD45陰性細胞を採取し、ラット肝幹細胞として本実験に用いた。
(1)で作製した肝線維化モデルラットに、(2)で調製したGFP標識肝幹細胞を、200μlのDME/F12培地中に2×106個の濃度で局所移植した。
肝幹細胞の移植後24時間目から、ビタミンA結合リポソーム内包siRNAgp46(VA-lip siRNAgp46)またはmockとしてVA-lip siRNAscrambleを1日おきに、合計12回尾静脈投与した。投与したsiRNAの濃度は、ラット体重に対して0.75mg/kgで使用した。ビタミンAおよびリポソーム(LipoTrust、北海道システム・サイエンス、Sapporo、Japan)およびsiRNAのモル比は11.5:11.5:1とした。
(3)で12回目のVA-lip siRNAgp46投与が終了した24時間後(すなわち総胆管結紮後52日目)に、GFP発現肝幹細胞を移植した総胆管結紮ラットの肝臓を採取した。採取した肝臓をOCTコンパウンドを用いて封埋した後、凍結切片を作製した。肝臓切片を4%パラホルムアルデヒドで固定した。切片の一部は、常法により、アザン染色に供した。切片の別の一部は5%ヤギ血清入りPBSでブロッキングを施し、PBSで洗浄した後、マウスモノクローナル抗α平滑筋アクチン(α-SMA)抗体(Sigma)、マウスモノクローナル抗グリア線維性酸性タンパク質(GFAP)抗体(Sigma)、ウサギポリクローナル抗アルブミン抗体 (MP Biomedicals)、マウスモノクローナル抗CK19抗体(Novocastra)もしくはマウスモノクローナル抗血管内皮カドヘリン(ve-CAD、Vascular Endothelial Cadherin)抗体(Santa cruz)を用いて、4℃で一晩反応させた。PBSで洗浄した後、Alexa555標識ヤギ抗マウスIgG抗体もしくはAlexa555標識ヤギ抗ウサギIgG抗体(いずれもInvitrogen)を室温で60分間反応させた。PBSで洗浄した後、ProLong(R) Gold with DAPI(Invitrogen)を用いて封入して、蛍光顕微鏡で観察を行った。切片の一部は、α-SMA抗体(Dako)と反応させた後、ヤギ抗ウサギ抗体との反応に代えて、ジアミノベンジジン(DAB)で発色させ、さらにヘマトキシリンで核染色を行った。
図1は、被験ラットから採取した肝臓の外観とそのその代表的切片のアザン染色像を表す。VA-lip siRNAscrambleを投与した群では、肝臓は萎縮し、表面が不整であり、組織中にアザン染色像において青色に染色された細胞外マトリックスの蓄積が広範囲にみられ、肝小葉構造も乱れていた。これに対し、VA-lip siRNAgp46を投与した群においては、外観的な萎縮が認められず、表面はなめらかであり、組織中に細胞外マトリックスの蓄積はほとんどみられず、VA-lip siRNAscramble投与群に比べ線維化領域の明らかな縮小がみられた。また、中心静脈から放射状に類洞が走行する正常な肝小葉構造が回復していることが明確に認められた。
図2は、α-SMA抗体のDAB染色像である。青色の部分はヘマトキシリンで染色された核を表し、濃い茶色の部分がα-SMA陽性領域である。α-SMAは活性化星細胞のマーカーとして知られており、α-SMA陽性領域には活性化星細胞が存在すると考えられる。VA-lip siRNAgp46投与群において、VA-lip siRNAscrambleと比較して顕著な活性化星細胞の減少が見られた。
図4は、GFP標識肝幹細胞移植部位の明視野像とGFP蛍光像である。VA-lip siRNAscramble投与群では、特に血管周囲などにおいて細胞外マトリックスの沈着のために細胞の形状がぼやけ、類洞も乱雑に走行しているのに対し、VA-lip siRNAgp46投与群では、はっきりした細胞形状と、中心静脈から放射状に走行する類洞構造が見られた。またVA-lip siRNAscramble投与群ではGFPの発色が見られなかったのに対し、VA-lip siRNAgp46投与群では、組織全体に渡ってGFPの発色が見られた。
図6は、VA-lip siRNAgp46投与群におけるDAPI、GFPの蛍光像とα-SMA抗体による蛍光染色像を倍率200倍で比較したものである。α-SMAを発現している細胞は、GFPを発現していなかった。図5および6の結果は、肝星細胞が肝幹細胞に由来するものではないことを示唆するものである。
図8はVA-lip siRNAgp46投与群におけるDAPI、GFPの蛍光像とCK19抗体による蛍光染色像を倍率200倍で比較したものである。CK19は胆管上皮細胞のマーカーであるが、胆管を構成するCK19陽性細胞は、GFPを発現していた。
図10は、VA-lip siRNAgp46投与群の細胞移植しなかった部位におけるDAPI、GFPの蛍光像とアルブミン抗体による蛍光染色像を倍率200倍で比較したものである。細胞移植しなかった部位においては、GFP発現細胞は観察されなかった。
GFPを発現する細胞は、移植した肝幹細胞由来の細胞であることから、VA-lip siRNAgp46の投与により、細胞移植部位において、線維化領域の縮小とともに肝幹細胞が肝実質細胞、胆管上皮細胞および血管上皮細胞へ分化することにより、正常な肝臓組織が再生されることが示された。すなわち、VA-lip siRNAgp46投与による治療は、肝線維症の治癒のみならず、肝再生をも誘起することが明らかとなった。また、VA-lip siRNAscramble投与群で肝幹細胞が検出できなかったこと(図3)は、VA-lip siRNAgp46による線維化領域の縮小が、肝幹細胞の増殖・分化に深く関与していることを示唆している。
(1)ラット膵星細胞(PSC)の単離
ラット膵星細胞(PSC)を、既報(Apte et al. Gut 1998;43:128-133)に従い、濃度勾配遠心分離法を用いて単離した。純度は顕微鏡観察、内在性VAの自己蛍光、および筋アクチン架橋タンパク質であるデスミンに対するモノクローナル抗体(1:25、Dako)を用いた免疫細胞化学法でアッセイした。細胞のバイアビリティはトリパンブルー排出でアッセイした。細胞純度およびバイアビリティは共に95%を上回っていた。細胞は、10%のウシ胎児血清(FBS)を添加したイスコーブ改変ダルベッコ培地(Iscove’s modified Dulbecco’s medium:IMDM)中で、37℃、95%大気/5%CO2の加湿環境下で培養した。
ラットpPSC(初代膵星細胞、primary PSC)を、Lab-Tekチャンバーカバーガラスに、チャンバー当たり1×104個となるように播種した。VA-lip siRNAgp46-FAMまたはLip siRNAgp46-FAMを、最終siRNA濃度が50nMとなるように細胞に添加した。細胞を、10%FBS含有DMEMで30分間培養し、培地を新鮮な培地に交換した。処理後30分および2時間において、細胞をPBSで3回洗浄し、4%のパラホルムアルデヒドで、25℃で15分間処理して固定した。固定後、細胞をPBSで3回洗浄し、ProLong(R) Gold with DAPI(Invitrogen)に1分間曝露して核染色した。FAM標識siRNAgp46の細胞内局在を蛍光顕微鏡(Keyence, BZ-8000)を用いてアッセイした。
ラットpPSC(1×104個)を、10%FBSの存在下、VA-lip siRNAgp46-FAM(50nMのsiRNA)で処理し、30分間培養した。ブロッキングアッセイのため、VA-lip siRNAgp46-FAMの添加前に、1×104個の細胞をマウス抗RBP抗体(10μg/ml、BD Pharmingen)またはネガティブコントロールであるマウスIgG1(10μg/ml、Dako)で30分間処理した。VA-lip siRNAgp46-FAM処理細胞の平均蛍光強度(MFI)をFACScalibur with CellQuest software(Becton Dickinson)を用いてアッセイした。
siRNAgp46のノックダウン効果を評価するため、ウェスタンブロッティング実験を行った。具体的には、VA-lip siRNAgp46(1nM、5nM、50nM)、VA-lip-siRNArandom(50nM)およびLip-siRNAgp46(50nM)でそれぞれ30分処理したPSCのタンパク質抽出物を4/20 SDS-ポリアクリルアミドゲルで分離し、ニトロセルロース膜上に転写し、HSP47(gp46)に対する抗体(Stressgen)またはβ-アクチンに対する抗体(Cell Signaling)でプローブした後、ペルオキシダーゼ結合抗体(Oncogene Research Product, Boston, MA)を二次抗体として標識した。最終的に、細胞をECLウェスタンブロッティング検出システム(Amersham Life Science, Arlington Heights, IL)で可視化した。
ラットpPSCを6ウェル組織培養プレートに、10%FBS含有DMEM中5×104個/ウェルの密度で播種した。24時間の培養後、ラットpPSCをVA-lip siRNAgp46(50nMのsiRNA)またはVA-lip siRNArandom(50nMのsiRNA)で処理した。細胞を10%FBS含有DMEM中で30分間培養し、その後培地を新鮮な培地と交換した。処理の72時間後、細胞をPBSで3回洗浄し、ウェルに沈着したコラーゲンを、既報(Williams et al. Gut 2001;49:577-583)に従ってシリウスレッド(Biocolor, Belfast, UK)で染色した。結合しなかった染料を洗浄して除去し、結合複合体を0.5%の水酸化ナトリウムに溶解した。コラーゲンを540nmの吸光光度分析で定量し、結果を未処理コントロールに対するパーセンテージで表した。
図11は、FAM標識されたsiRNAの細胞内分布を表す蛍光像である。左の2つはVA-lip siRNAgp46-FAMで処理したPSCの蛍光像であり、右の2つはLip siRNAgp46-FAMで処理したPSCの蛍光像である。上の2つはそれぞれにおける処理後30分後の像であり、下の2つは処理後2時間後の像である。VA-lip siRNAgp46-FAMでは、処理後30分で細胞質内にぼんやりした顆粒状パターンのFAMの緑色蛍光が観察され、処理後2時間でより濃い顆粒状パターンが核周辺領域に観察された。それに比べ、Lip siRNAgp46-FAM処理群においては、処理後30分では緑色蛍光が観察されず、処理後2時間における核周辺の蛍光はぼんやりしたものであった。
図13Bは、抑制効果の持続時間を確認するウェスタンブロッティングの結果を表す。VA-lip siRNAgp46で処理した場合、処理後72時間培養した細胞まではgp46の顕著な抑制が観察された。従って、処理後少なくとも72時間までは、gp46の発現抑制効果が持続することが確認できた。
上記の結果から、in vitroにおいて、VA-lip siRNAgp46は、RBPレセプター媒介性の取り込みによってPSCに特異的に取り込まれてgp46の発現を抑制し、その結果コラーゲンの産生を顕著に抑制することがわかる。これは、VA-lip siRNAgp46が膵線維症に冒された膵臓において、コラーゲンを低減し得ることを示唆するものである。
(1)膵臓線維化モデルラットの作製
体重が150~200gの雄Lewisラット(Charles River)を用いた。既報(Inoue et al. Pancreas 2002;25:e64-70)に従って、二塩化ジブチルスズ(Dibutyltin dichloride、DBTC)を1部のエタノールに溶かしたのち、2部のグリセロールおよび2部のジメチルスルホキシド(DMSO)と混合した溶液(DBTC溶液)を調製し、5mg(DBTC)/kg(体重)に相当する量を、ラット右頸動脈よりシリンジを用いて投与した。
DBTC投与開始から43日後、重篤な膵臓の線維化が観察された時点で、DBTC処置ラットに1μl/g体重のVA-lip siRNAgp46-FITCまたはLip siRNAgp46-FITCを尾静脈より投与した。投与は常圧下で行われ、1回当たり0.75mg/kgのsiRNAを1日おきに3回投与した。最後の投与の24時間後、ラットを生理食塩水の灌流により殺処理し、膵臓および他の臓器(肝臓、肺、脾臓および網膜)を採取した。臓器標本を10%のパラホルムアルデヒドで固定し、パラフィン包埋切片をアザン-マロリー染色を用いて染色した。モノクローナル抗α-SMA抗体(1:1000、Sigma)、抗CD68抗体(1:500、Dako)および抗FITC抗体(1:500、Abcam)をそれぞれ用いたデキストランポリマー法、およびEnvision Kit(Dako)によって免疫組織染色を行い、続いてDAB(和光純薬工業、Osaka, Japan)による発色およびギルへマトキシリン液(和光純薬工業)による核染色を行った。
in vivoにおけるsiRNAgp46による発現抑制の持続時間を評価するため、VA-lip siRNAgp46の静脈内投与後0、1、2、3、4日後における膵臓からのタンパク質抽出物について、例3.(4)と同様にウェスタンブロッティングを行った。
3群のラット(1群当たりn=6)を組織学的評価に用いた。DBTC投与の43日後、各群をそれぞれPBS、VA-lip siRNArandomおよびVA-lip siRNAgp46の10回投与(0.75mg/kgのsiRNA、1日おきに3回投与)で処置した。全ての投与は尾静脈より常圧下で、1μl/g体重の量で行った。膵臓を10%のパラホルムアルデヒドで固定し、パラフィン包埋後、切片をアザン-マロリー染色およびヘマトキシリン-エオシン染色を用いて染色した。免疫組織染色は、モノクローナル抗α-SMA抗体(1:1000、Sigma)を用いたデキストランポリマー法、およびEnvision Kit(Dako)によって行い、続いてDAB(和光純薬工業、Osaka, Japan)による発色およびギルへマトキシリン液(和光純薬工業)による核染色を行った。アザン-マロリー、ヘマトキシリン-エオシンおよびα-SMAによる染色領域の正確な定量のため、各ラットの膵臓切片ごとに6つの低倍率視野(×100)を無作為に選択し、顕微鏡(Axioplan 2; Carl Zeiss, Inc)で観察した。デジタル画像を、デジタルTVカメラシステム(Axiocam High Resolution color, Carl Zeiss, Inc.)を用いたビデオ記録システムによって撮像した。自動ソフトウェア分析プログラム(KS400, Carl Zeiss, Inc.)を用いて、デジタル顕微鏡写真中の、アザン-マロリーおよびα-SMAによって染色された領域の割合を決定した。
ヒドロキシプロリン含有量は、既報(Weidenbach et al. Digestion 1997;58:50-57)に従い、Weidenbach法によって決定した。簡潔には、膵臓の細胞破砕物を3000rpmで15分間遠心し、ペレットを6NのHCl中で16時間、96℃で完全に加水分解し、pHを6.5~7.5に調節した後、再度遠心(3000rpmで15分間)した。25μlのアリコートを60℃で乾燥させ、沈殿物を1.2mlの50%イソプロパノールに溶解し、200mlの0.56% chloramine T Solution(Sigma)入り酢酸・クエン酸緩衝液pH6.0中でインキュベートした。25℃で10分間インキュベートした後、1mlのエールリッヒ試薬を加え、混合物を50℃で90分間インキュベートした。冷却後、560nmの波長の吸収を計測した。
コラーゲナーゼ活性の計測は、既報(Iredale et al. J.Clin.Invest. 1998;102:538-549)の変法により行った。簡潔には、野生型ラットおよび膵臓線維化モデルラットから採取し、液体窒素冷凍された膵臓を、セリン-およびチオール-プロテアーゼ阻害剤(PMSF 0.1mM、ロイペプチン10μM、ペプスタチンA 10μM、アプロチニン25μg/ml、ヨードアセトアミド0.1mM)を含むサンプルバッファ(50mM Tris、pH7.6、0.25%Triton X-100、0.15M NaCl、10mM CaCl2)中で、氷上で破砕した。細胞破砕物を4℃、14000gで30分間遠心して細胞残屑およびタンパク質凝集体を取り除いた。膵臓の細胞破砕物中のコラーゲナーゼ活性を、EnzCheck Collagenase Assay Collagen Conjugate kit (Molecular Probes)を用いて、取扱説明書に従って決定した。平行して適切なネガティブコントロールおよびポジティブコントロール(細菌性コラーゲナーゼ)を用いて分析し、結果をタンパク質のmgごとの分解コラーゲンの蛍光(血清アルブミン標準と比較した280nmの光学濃度によって決定)によって表した。
膵臓の各連続セクションにおいて活性化星細胞およびsiRNAgp46-FITCを免疫染色した結果、VA-lip siRNAgp46-FITC投与群においては、活性化星細胞(α-SMA陽性の細胞)が集まっている領域において、FITC陽性の細胞が同定されたのに対し、Lip siRNAgp46-FITC投与群においては、α-SMA陽性の領域において同定されたFITC陽性細胞はごく僅かであった(図15AおよびB)。
α-SMA陽性領域におけるFITC陽性細胞は、肝臓標本においても観察された(図15C)。この結果は、DBTCによって膵線維化のみならず肝硬変も誘導されるという知見と合致する。肺および脾臓を含むラットの他の臓器においては、マクロファージが浸潤している領域(CD68陽性細胞)においてFITC染色された細胞はわずかであったことから(図15DおよびE)、マクロファージによるsiRNAgp46-FITCの非特異的取り込みが示唆される。網膜はFITC染色に陰性であり(図15F)、このことは肝硬変におけるVA-lip siRNAgp46-FAMを用いた知見と合致する。おそらく、血液網膜関門の透過性の低さにより、眼球は独立した系を構築しているためと考えられる。
上記の結果に鑑みると、VA-lip siRNAgp46による処置により、siRNAgp46が活性化膵星細胞(aPSC)に特異的に取り込まれてgp46の発現を抑制し、その結果aPSCからのからのコラーゲン分泌を抑制することで膵線維化の改善に顕著な効果を発揮することがわかる。さらに、おそらくコラーゲン分泌の減少に起因してaPSCの顕著な減少が観察された。そして特筆すべきことに、VA-lip siRNAgp46による処置は、膵線維化の改善のみならず、膵臓組織の再生も誘導することが証明された。上記例2における結果と合わせ考えれば、これらの結果は、線維化組織において蓄積したコラーゲンを低減することにより、組織非特異的に線維化組織から正常組織を再生し得ることを示すものである。
活性化肝星細胞(aHSC)を、種々の密度の肝前駆細胞と共培養し、肝前駆細胞の分化に細胞周囲のスペースの有無が与える影響を検討した。肝前駆細胞としては、上記例2(2)で得たGFP標識ラット肝幹細胞を、aHSCとしては、SDラットから採取したHSCを培養し、1回継代したものをそれぞれ用いた。aHSCは以下のように採取・培養した。まず、SDラットにEGTA溶液およびコラゲナーゼ溶液を灌流した後、肝臓を採取し、採取した肝臓を細切した後、セルストレーナー(孔径100μm)で濾過した。得られた細胞懸濁液にHBSS+0.25%BSA溶液を加えて、4℃、500rpmで2分間遠心した。上清を採取して、4℃、1300rpmで5分間遠心を行った。上清を除去した後、HBSS+0.25%BSA溶液を加え、Nycodenzの濃度が13.2%になるように28.7% Nycodenz溶液(Axis Shield, Oslo, Norway)を加えて混合した。HBSS+0.25%BSA溶液を重層した後、4℃、1400×gで20分間遠心した。遠心終了後、中間層を採取して、Dulbecco’s Modified Eagle's medium(DMEM)+10%ウシ胎児血清(FBS)培地を用いて、5日間培養した。培養5日目に継代を行い、その細胞を本実験に用いた。
別な実験では、共培養10日目に、Premix WST-1 Cell Proliferation Assay System (Takara, Tokyo, Japan)を使用して、マイクロプレートリーダー(Bio-Rad Laboratories, Hercules, CA, USA)を用いて細胞増殖の測定を行った。結果を図21に示す。
以上の結果から、活性化星細胞が幹細胞の増殖・分化を誘導すること、および、幹細胞の増殖・分化に幹細胞周囲の物理的スペースの有無が重要な影響を及すことが判明した。これは、上記各例の結果と合わせ考えると、コラーゲン低減物質によって線維化組織における線維組織が縮小し、幹細胞の周囲にスペースが生じた結果、幹細胞が増殖・分化し、正常組織が再生することを示すものである。
Claims (9)
- コラーゲン低減物質を含む、線維化組織から正常組織を再生するための医薬組成物。
- コラーゲン低減物質が、コラーゲン産生細胞によるコラーゲン産生を抑制する物質、コラーゲンの分解を促進する物質、およびコラーゲン分解阻害物質を抑制する物質からなる群から選択される、請求項1に記載の医薬組成物。
- 線維化組織におけるコラーゲン産生細胞に対する標的化剤をさらに含む、請求項1または2に記載の医薬組成物。
- 標的化剤がレチノイドである、請求項3に記載の医薬組成物。
- 線維化組織が、線維化刺激を継続的に受けている、請求項1~4のいずれか一項に記載の医薬組成物。
- [規則91に基づく訂正 05.10.2012]
線維化組織に蓄積されたコラーゲンが低減されて生成される、幹細胞の増殖・分化用のスペースにおいて、線維化組織から正常組織を再生するための、請求項1~5のいずれか一項に記載の医薬組成物。 - コラーゲン産生細胞によるコラーゲン産生を抑制する物質が、TGFβ阻害物質、HGFまたはその産生促進物質、PPARγリガンド、アンジオテンシン阻害物質、PDGF阻害物質、リラキシンまたはその産生促進物質、細胞外マトリックス成分の産生・分泌を阻害する物質、細胞活性抑制物質、細胞増殖抑制物質、ならびにアポトーシス誘導物質からなる群から選択される、請求項2~6のいずれか一項に記載の医薬組成物。
- コラーゲンの分解を促進する物質がコラゲナーゼまたはその産生促進物質である、請求項2~6のいずれか一項に記載の医薬組成物。
- コラーゲン分解阻害物質を抑制する物質がTIMP阻害物質である、請求項2~6のいずれか一項に記載の医薬組成物。
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/813,907 US9408864B2 (en) | 2010-08-05 | 2011-08-05 | Composition for regenerating normal tissue from fibrotic tissue |
CN2011800385742A CN103068402A (zh) | 2010-08-05 | 2011-08-05 | 用于由纤维化组织再生正常组织的组合物 |
KR1020137004671A KR101947785B1 (ko) | 2010-08-05 | 2011-08-05 | 섬유화 조직으로부터 정상 조직을 재생하기 위한 조성물 |
CA2807033A CA2807033C (en) | 2010-08-05 | 2011-08-05 | Composition for regenerating normal tissue from fibrotic tissue |
KR1020217024745A KR20210099208A (ko) | 2010-08-05 | 2011-08-05 | 섬유화 조직으로부터 정상 조직을 재생하기 위한 조성물 |
DK11814740.4T DK2601971T3 (da) | 2010-08-05 | 2011-08-05 | Sammensætning til regenerering af normalt væv fra fibrotisk væv |
SI201131323T SI2601971T1 (en) | 2010-08-05 | 2011-08-05 | A composition for regenerating normal tissue from fibrotic tissue |
KR1020207014125A KR20200057109A (ko) | 2010-08-05 | 2011-08-05 | 섬유화 조직으로부터 정상 조직을 재생하기 위한 조성물 |
RS20171112A RS56493B1 (sr) | 2010-08-05 | 2011-08-05 | Kompozicija za regenerisanje normalnog tkiva iz fibroznog tkiva |
LTEP11814740.4T LT2601971T (lt) | 2010-08-05 | 2011-08-05 | Kompozicija, skirta normalių audinių regeneravimui iš fibrozinių audinių |
EP11814740.4A EP2601971B1 (en) | 2010-08-05 | 2011-08-05 | Composition for regeneratng normal tissue from fibrotic tissue |
AU2011286636A AU2011286636B2 (en) | 2010-08-05 | 2011-08-05 | Composition for regenerating normal tissue from fibrotic tissue |
PL11814740T PL2601971T3 (pl) | 2010-08-05 | 2011-08-05 | Kompozycja do regeneracji prawidłowej tkanki z tkanki zwłókniałej |
KR1020227011292A KR20220047888A (ko) | 2010-08-05 | 2011-08-05 | 섬유화 조직으로부터 정상 조직을 재생하기 위한 조성물 |
NO11814740A NO2601971T3 (ja) | 2010-08-05 | 2011-08-05 | |
ES11814740.4T ES2652348T3 (es) | 2010-08-05 | 2011-08-05 | Composición para regenerar tejido normal a partir de tejido fibrótico |
RU2013109370A RU2650796C2 (ru) | 2010-08-05 | 2011-08-05 | Композиция для восстановления нормальной ткани из фиброзной ткани |
KR1020197003727A KR20190018545A (ko) | 2010-08-05 | 2011-08-05 | 섬유화 조직으로부터 정상 조직을 재생하기 위한 조성물 |
US13/789,032 US20160015656A2 (en) | 2010-08-05 | 2013-03-07 | Composition for regenerating normal tissue from fibrotic tissue |
US15/208,440 US9926561B2 (en) | 2010-08-05 | 2016-07-12 | Composition for regenerating normal tissue from fibrotic tissue |
HRP20171556TT HRP20171556T1 (hr) | 2010-08-05 | 2017-10-13 | Pripravak za regeneriranje normalnog tkiva iz fibrotičnog tkiva |
CY20171101142T CY1119527T1 (el) | 2010-08-05 | 2017-11-02 | Συνθεση για την αναγεννηση φυσιολογικου ιστου απο ινωτικο ιστο |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-175920 | 2010-08-05 | ||
JP2010175920 | 2010-08-05 | ||
JP2010230020A JP5950428B2 (ja) | 2010-08-05 | 2010-10-12 | 線維化組織から正常組織を再生するための組成物 |
JP2010-230020 | 2010-10-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/492,424 Continuation-In-Part US9393315B2 (en) | 2004-12-22 | 2012-06-08 | Compounds for targeting drug delivery and enhancing siRNA activity |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/813,907 A-371-Of-International US9408864B2 (en) | 2010-08-05 | 2011-08-05 | Composition for regenerating normal tissue from fibrotic tissue |
US13/789,032 Continuation-In-Part US20160015656A2 (en) | 2010-08-05 | 2013-03-07 | Composition for regenerating normal tissue from fibrotic tissue |
US15/208,440 Continuation US9926561B2 (en) | 2010-08-05 | 2016-07-12 | Composition for regenerating normal tissue from fibrotic tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012018115A1 WO2012018115A1 (ja) | 2012-02-09 |
WO2012018115A9 true WO2012018115A9 (ja) | 2013-01-10 |
Family
ID=45559610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/067953 WO2012018115A1 (ja) | 2010-08-05 | 2011-08-05 | 線維化組織から正常組織を再生するための組成物 |
Country Status (20)
Country | Link |
---|---|
US (2) | US9408864B2 (ja) |
EP (1) | EP2601971B1 (ja) |
JP (1) | JP5950428B2 (ja) |
KR (5) | KR20200057109A (ja) |
CN (1) | CN103068402A (ja) |
AU (1) | AU2011286636B2 (ja) |
CA (1) | CA2807033C (ja) |
CY (1) | CY1119527T1 (ja) |
DK (1) | DK2601971T3 (ja) |
ES (1) | ES2652348T3 (ja) |
HR (1) | HRP20171556T1 (ja) |
LT (1) | LT2601971T (ja) |
NO (1) | NO2601971T3 (ja) |
PL (1) | PL2601971T3 (ja) |
PT (1) | PT2601971T (ja) |
RS (1) | RS56493B1 (ja) |
RU (1) | RU2650796C2 (ja) |
SI (1) | SI2601971T1 (ja) |
TW (1) | TWI589291B (ja) |
WO (1) | WO2012018115A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
JP6023824B2 (ja) * | 2010-08-05 | 2016-11-09 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
WO2014024820A1 (ja) * | 2012-08-06 | 2014-02-13 | 塩野義製薬株式会社 | 新規慢性腎臓病治療用医薬組成物及び新規慢性腎臓病治療薬のスクリーニング方法 |
JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
EP3127915B1 (en) | 2014-04-02 | 2020-08-26 | Nitto Denko Corporation | Rbp-derived targeting molecule and utilization thereof |
CA2943733C (en) | 2014-04-07 | 2022-03-01 | Nitto Denko Corporation | Polymer-based hydrotropes for hydrophobic drug delivery |
US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
JP6833456B2 (ja) * | 2016-11-02 | 2021-02-24 | 日東電工株式会社 | 皮膚線維症処置剤 |
MX2019008949A (es) | 2017-01-27 | 2019-10-07 | Stemrim Inc | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. |
KR102367324B1 (ko) | 2021-07-28 | 2022-02-24 | 현대글로비스 주식회사 | 차폐 슬리브를 구비한 전기차 배터리 운송용기 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966773A (en) | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
US5811119A (en) | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
US20040028682A1 (en) | 1989-09-29 | 2004-02-12 | Border Wayne A. | Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix |
ATE154514T1 (de) | 1989-09-29 | 1997-07-15 | Jolla Cancer Res Found | Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix |
AU670777B2 (en) | 1992-04-16 | 1996-08-01 | Ortho Pharmaceutical Corporation | Aqueous gel vehicles for retinoids |
JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
JPH08268906A (ja) | 1995-03-31 | 1996-10-15 | Sumitomo Pharmaceut Co Ltd | 肺線維症予防剤 |
US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
US5851538A (en) | 1995-12-29 | 1998-12-22 | Advanced Polymer Systems, Inc. | Retinoid formulations in porous microspheres for reduced irritation and enhanced stability |
US6183774B1 (en) | 1996-01-31 | 2001-02-06 | Collaborative Laboratories, Inc. | Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts |
AU756301B2 (en) | 1997-08-20 | 2003-01-09 | Somagenics, Inc. | Antisense and antigene therapeutics with improved binding properties and methods for their use |
JPH11269076A (ja) | 1998-01-22 | 1999-10-05 | Seikagaku Kogyo Co Ltd | 抗線維化剤 |
WO2000064478A1 (fr) | 1999-04-27 | 2000-11-02 | Mitsubishi Pharma Corporation | Medicaments destines a soigner et a prevenir les maladies du foie |
US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
AU2001247924A1 (en) | 2000-03-29 | 2001-10-08 | Aradigm Corporation | Cationic liposomes |
JP2002047211A (ja) | 2000-08-04 | 2002-02-12 | Japan Science & Technology Corp | 脂溶性物質と生理活性高分子物質結合体および細胞核内への導入方法 |
US20030096739A1 (en) | 2001-04-13 | 2003-05-22 | Morris Patricia L. | Nuclear receptor-mediated introduction of a PNA into cell nuclei |
JP4547696B2 (ja) | 2001-06-07 | 2010-09-22 | 第一三共株式会社 | 肝硬変予防・治療剤 |
JP2002371006A (ja) | 2001-06-11 | 2002-12-26 | Mochida Pharmaceut Co Ltd | 肺線維症予防および/または進行防止剤 |
JP2003119138A (ja) | 2001-10-09 | 2003-04-23 | Tohoku Techno Arch Co Ltd | 間質性肺炎および/または肺線維症の予防治療剤 |
ATE359829T1 (de) | 2001-10-30 | 2007-05-15 | Nektar Therapeutics Al Corp | Wasserlösliche polymerkonjugate von retinoesäure |
CN1612930A (zh) | 2001-11-21 | 2005-05-04 | 三菱化学株式会社 | 抑制基因表达的方法 |
JP3803318B2 (ja) | 2001-11-21 | 2006-08-02 | 株式会社RNAi | 遺伝子発現阻害方法 |
WO2003045383A1 (en) | 2001-11-26 | 2003-06-05 | Arachnova Therapeutics Ltd. | Use of ppar activators for the treatment of pulmonary fibrosis |
JP4814520B2 (ja) | 2002-05-15 | 2011-11-16 | エンドサイト,インコーポレイテッド | ビタミン−マイトマイシン結合体 |
US20080051428A1 (en) * | 2002-05-15 | 2008-02-28 | Davis Paul J | Pyrroloquinoline quinone drugs and methods of use thereof |
EP1565489B1 (en) | 2002-06-19 | 2010-11-17 | Raven Biotechnologies, Inc. | Internalizing antibodies specific for the RAAG10 cell surface target |
CA2496314A1 (en) | 2002-08-27 | 2004-03-11 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
CA2496547A1 (en) | 2002-08-29 | 2004-03-11 | University Of Southampton | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
EP2517729A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
JP2006522158A (ja) | 2003-04-03 | 2006-09-28 | アルナイラム ファーマシューティカルズ インコーポレイテッド | iRNA複合体 |
WO2005084702A1 (ja) | 2004-03-02 | 2005-09-15 | Hokkaido Technology Licensing Office Co., Ltd. | 臓器線維症予防・治療剤 |
SI2730277T1 (sl) | 2004-12-22 | 2020-07-31 | Nitto Denko Corporation | Nosilec zdravila in komplet za nosilec zdravila za zaviranje fibroze |
US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
JP2009221164A (ja) | 2008-03-17 | 2009-10-01 | Nitto Denko Corp | 肺線維症処置剤 |
US20130171240A1 (en) | 2004-12-22 | 2013-07-04 | Nitto Denko Corporation | Drug carrier and drug carrier kit for inhibiting fibrosis |
US7854929B2 (en) * | 2005-01-21 | 2010-12-21 | The Research Foundation Of State University Of New York | Method for treating lateral epicondylitis using collagenase |
EA013907B1 (ru) * | 2005-10-26 | 2010-08-30 | Мерк Сероно С.А. | Сульфонамидные производные и их применение для модулирования металлопротеаз |
GB0524987D0 (en) | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
JP5342834B2 (ja) | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
US20130210744A1 (en) | 2007-03-30 | 2013-08-15 | Nitto Denko Corporation | Targeting agent for cancer cell or cancer-associated fibroblast |
JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
US20090232781A1 (en) * | 2008-03-13 | 2009-09-17 | Yu-Show Fu | Treatment of liver diseases through transplantation of human umbilical mesenchymal stem cells |
AU2008359989A1 (en) | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
EP2337587A4 (en) | 2008-09-12 | 2015-02-18 | Nitto Denko Corp | IMAGING AGENTS FOR FIBROTIC DISEASES |
ES2562499T3 (es) | 2009-12-09 | 2016-03-04 | Nitto Denko Corporation | Modulación de la expresión de HSP47 |
KR101967868B1 (ko) | 2010-06-17 | 2019-08-19 | 닛토덴코 가부시키가이샤 | 신장 섬유증 치료 물질 |
US20160015656A2 (en) | 2010-08-05 | 2016-01-21 | Nitto Denko Corporation | Composition for regenerating normal tissue from fibrotic tissue |
JP5950428B2 (ja) | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
CN102370686B (zh) * | 2010-08-26 | 2013-09-18 | 上海中医药大学附属曙光医院 | 治疗慢性肝病的药物组合物及其应用 |
TWI658830B (zh) * | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Hsp47表現調控強化用類視色素脂質體 |
RU2639459C2 (ru) | 2011-06-21 | 2017-12-21 | Нитто Денко Корпорейшн | Апоптоз-индуцирующее средство |
CA2856016C (en) | 2011-11-18 | 2020-09-22 | Tokiyoshi AYABE | Agent for treating fibrosis of the intestine |
-
2010
- 2010-10-12 JP JP2010230020A patent/JP5950428B2/ja active Active
-
2011
- 2011-08-04 TW TW100127765A patent/TWI589291B/zh active
- 2011-08-05 DK DK11814740.4T patent/DK2601971T3/da active
- 2011-08-05 CA CA2807033A patent/CA2807033C/en active Active
- 2011-08-05 KR KR1020207014125A patent/KR20200057109A/ko active Application Filing
- 2011-08-05 KR KR1020137004671A patent/KR101947785B1/ko active IP Right Grant
- 2011-08-05 KR KR1020227011292A patent/KR20220047888A/ko not_active Application Discontinuation
- 2011-08-05 WO PCT/JP2011/067953 patent/WO2012018115A1/ja active Application Filing
- 2011-08-05 CN CN2011800385742A patent/CN103068402A/zh active Pending
- 2011-08-05 SI SI201131323T patent/SI2601971T1/en unknown
- 2011-08-05 KR KR1020217024745A patent/KR20210099208A/ko not_active Application Discontinuation
- 2011-08-05 PT PT118147404T patent/PT2601971T/pt unknown
- 2011-08-05 LT LTEP11814740.4T patent/LT2601971T/lt unknown
- 2011-08-05 PL PL11814740T patent/PL2601971T3/pl unknown
- 2011-08-05 EP EP11814740.4A patent/EP2601971B1/en active Active
- 2011-08-05 KR KR1020197003727A patent/KR20190018545A/ko active Application Filing
- 2011-08-05 ES ES11814740.4T patent/ES2652348T3/es active Active
- 2011-08-05 AU AU2011286636A patent/AU2011286636B2/en active Active
- 2011-08-05 RS RS20171112A patent/RS56493B1/sr unknown
- 2011-08-05 US US13/813,907 patent/US9408864B2/en active Active
- 2011-08-05 RU RU2013109370A patent/RU2650796C2/ru active
- 2011-08-05 NO NO11814740A patent/NO2601971T3/no unknown
-
2016
- 2016-07-12 US US15/208,440 patent/US9926561B2/en active Active
-
2017
- 2017-10-13 HR HRP20171556TT patent/HRP20171556T1/hr unknown
- 2017-11-02 CY CY20171101142T patent/CY1119527T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5950428B2 (ja) | 線維化組織から正常組織を再生するための組成物 | |
JP5302187B2 (ja) | がん細胞および癌随伴線維芽細胞への標的化剤 | |
KR20110010692A (ko) | 폐섬유증 치료제 | |
KR102059054B1 (ko) | 장 섬유증 치료제 | |
JP6023824B2 (ja) | 線維化組織から正常組織を再生するための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180038574.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11814740 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2807033 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011286636 Country of ref document: AU Date of ref document: 20110805 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20137004671 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013109370 Country of ref document: RU Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011814740 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011814740 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13813907 Country of ref document: US |